; SourceControl.Exporter format version 1.1
Name=C91.1

Node:^VARWorkFlowPEP(0,"C91.1")
; Work Flow de Atendimento do PEP

Location:^VARWorkFlowPEP(0,"C91.1",1,1)
001:Sangue Periférico
002:1
004:10

Location:^VARWorkFlowPEP(0,"C91.1",2,1)
001:Medula Óssea
002:1
004:20

Location:^VARWorkFlowPEP(0,"C91.1",3,1)
001:Exames de Imagem
002:1
004:68

Location:^VARWorkFlowPEP(0,"C91.1",4,1)
001:Avaliação clínica e sintomas B
002:1
004:8

Location:^VARWorkFlowPEP(0,"C91.1",5,1)
001:Anemia ou Trombocitopenia Auto-Imune
002:10
003:1
004:150

Location:^VARWorkFlowPEP(0,"C91.1",6,1)
001:Análise Citogenética
002:1
004:60

Location:^VARWorkFlowPEP(0,"C91.1",7,1)
001:Exames Laboratoriais Gerais
002:1
004:13

Location:^VARWorkFlowPEP(0,"C91.1",8,1)
001:Análise de Biologia Molecular
002:1
004:65

Location:^VARWorkFlowPEP(0,"C91.1",9,1)
001:Performance Status
002:10
003:4
004:5000

Location:^VARWorkFlowPEP(0,"C91.1",10,1)
001:Imunofenotipagem
002:10
003:1
004:100

Location:^VARWorkFlowPEP(0,"C91.1",11,1)
001:Hemograma
002:10
003:1
004:1

Location:^VARWorkFlowPEP(0,"C91.1",12,1)
001:53
002:5
003:11
004:120
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",13,1)
001:54
002:5
003:11
004:130
005:0
007:1
008:1
009:12
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",14,1)
001:55
002:5
003:11
004:140
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",15,1)
001:56
002:5
003:11
004:150
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",16,1)
001:57
002:5
003:11
004:160
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",17,1)
001:58
002:5
003:11
004:170
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",18,1)
001:59
002:5
003:11
004:180
005:0
006:100
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",19,1)
001:60
002:5
003:11
004:190
005:0
007:1
008:1
016:Série Vermelha

Location:^VARWorkFlowPEP(0,"C91.1",20,1)
001:61
002:5
003:11
004:195
005:0
007:1
008:1
016:Série Branca
018:=
019:2
020:21;22;23;24;25;26;27;28;29;30
021:A contagem de Leucócitos foi de <sequencia> e a soma de todos os subtipos de glóbulos brancos foi de <campos>. Deseja prosseguir?

Location:^VARWorkFlowPEP(0,"C91.1",21,1)
001:62
002:5
003:11
004:210
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",22,1)
001:63
002:5
003:11
004:220
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",23,1)
001:64
002:5
003:11
004:230
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",24,1)
001:65
002:5
003:11
004:240
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",25,1)
001:66
002:5
003:11
004:250
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",26,1)
001:67
002:5
003:11
004:260
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",27,1)
001:68
002:5
003:11
004:270
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",28,1)
001:69
002:5
003:11
004:280
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",29,1)
001:70
002:5
003:11
004:290
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",30,1)
001:71
002:5
003:11
004:300
008:13
016:Série Branca

Location:^VARWorkFlowPEP(0,"C91.1",32,1)
001:73
002:5
003:11
004:320
005:0
007:1
008:1
009:100000
016:Série Plaquetária

Location:^VARWorkFlowPEP(0,"C91.1",33,1)
001:Quantidade absoluta de células com fenótipo<br>CD19+/CD5+/CD23+ no sangue periférico
002:3
003:1369
004:330
005:0
013:/ul
022:1

Location:^VARWorkFlowPEP(0,"C91.1",34,1)
001:Porcentagem dos linfócitos com fenótipo<br>CD19+/CD5+/CD23+ no sangue periférico
002:3
003:1369
004:340
005:0
006:100
007:1
013:% dos linfócitos
022:1

Location:^VARWorkFlowPEP(0,"C91.1",37,1)
001:Mielograma
002:10
003:2
004:370

Location:^VARWorkFlowPEP(0,"C91.1",38,1)
001:Imunofenotipagem de medula óssea
002:10
003:2
004:380

Location:^VARWorkFlowPEP(0,"C91.1",39,1)
001:Biopsia de Medula Óssea
002:10
003:2
004:390

Location:^VARWorkFlowPEP(0,"C91.1",40,1)
001:Porcentagem de linfócitos no mielograma
002:3
003:187
004:300
005:0
006:100
007:1
013:%
022:1

Location:^VARWorkFlowPEP(0,"C91.1",41,1)
001:O mielograma foi considerado normal?
002:11
003:187
004:410
022:1

Location:^VARWorkFlowPEP(0,"C91.1",42,1)
001:Celularidade global
002:9
003:41
004:420
014:Normal|Aumentada|Diminuída
015:0
022:0

Location:^VARWorkFlowPEP(0,"C91.1",43,1)
001:Série Eritroide
002:4
003:41
004:430
011:100
012:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",44,1)
001:Série Granulocítica
002:4
003:41
004:440
011:100
012:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",45,1)
001:Série Linfoide
002:4
003:41
004:450
011:100
012:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",46,1)
001:Serie Monocítica
002:4
003:41
004:460
011:100
012:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",47,1)
001:Serie Megacariocítica
002:4
003:41
004:470
011:100
012:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",48,1)
001:Observações
002:4
003:41
004:480
011:1000
012:5
022:0

Location:^VARWorkFlowPEP(0,"C91.1",49,1)
001:Conclusão
002:4
003:41
004:490
011:1000
012:5
022:0

Location:^VARWorkFlowPEP(0,"C91.1",54,1)
001:74
002:5
003:66
004:540
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",55,1)
001:77
002:5
003:66
004:543
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",56,1)
001:75
002:5
003:66
004:541
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",57,1)
001:76
002:5
003:66
004:542
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",60,1)
001:80
002:5
003:66
004:551
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",61,1)
001:81
002:5
003:66
004:548
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",63,1)
001:Há Infiltração por LLC na Biopsia?
002:11
003:189
004:630
022:1
023:1.1

Location:^VARWorkFlowPEP(0,"C91.1",64,1)
001:% de infiltração por linfócitos<br>na bióspia de medula óssea
002:3
003:63
004:640
005:1
006:100
013:%
022:1

Location:^VARWorkFlowPEP(0,"C91.1",65,1)
001:Observações
002:4
003:63
004:650
011:1000
012:5
022:1

Location:^VARWorkFlowPEP(0,"C91.1",66,1)
001:Realizou Imunohistoquimica?
002:11
003:63
004:660
022:1

Location:^VARWorkFlowPEP(0,"C91.1",68,1)
001:74
002:5
003:871
004:680
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",69,1)
001:Paciente tem Linfonodomegalia ao Exame Físico?
002:2
003:1517
004:5

Location:^VARWorkFlowPEP(0,"C91.1",71,1)
001:1;1
002:7
003:69
004:710
022:1

Location:^VARWorkFlowPEP(0,"C91.1",72,1)
001:1;2
002:7
003:69
004:720
022:1

Location:^VARWorkFlowPEP(0,"C91.1",73,1)
001:1;3
002:7
003:69
004:730
022:1

Location:^VARWorkFlowPEP(0,"C91.1",74,1)
001:1;4
002:7
003:69
004:740
022:1

Location:^VARWorkFlowPEP(0,"C91.1",75,1)
001:1;5
002:7
003:69
004:750
022:1

Location:^VARWorkFlowPEP(0,"C91.1",76,1)
001:1;6
002:7
003:69
004:760
022:1

Location:^VARWorkFlowPEP(0,"C91.1",77,1)
001:1;7
002:7
003:69
004:770
022:1

Location:^VARWorkFlowPEP(0,"C91.1",78,1)
001:1;8
002:7
003:69
004:780
022:1

Location:^VARWorkFlowPEP(0,"C91.1",79,1)
001:1;9
002:7
003:69
004:790
022:1

Location:^VARWorkFlowPEP(0,"C91.1",80,1)
001:1;10
002:7
003:69
004:800
022:1

Location:^VARWorkFlowPEP(0,"C91.1",81,1)
001:1;11
002:7
003:69
004:810
022:1

Location:^VARWorkFlowPEP(0,"C91.1",82,1)
001:Cervical Anterior Esquerdo
002:11
003:243
004:820
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",83,1)
001:Cervical Anterior Direito
002:11
003:243
004:830
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",84,1)
001:Cervical Posterior Esquerdo
002:11
003:243
004:840
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",85,1)
001:Cervical Posterior Direito
002:11
003:243
004:850
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",86,1)
001:Número de Linfonodos Aumentados
002:3
003:82
004:860
005:0
010:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",87,1)
001:Tamanho do Maior Linfonodo
002:3
003:82
004:870
005:0
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",88,1)
001:Tem doença "Bulky"?
002:11
003:82
004:880
022:1

Location:^VARWorkFlowPEP(0,"C91.1",89,1)
001:Observações
002:4
003:82
004:890
011:1000
012:5
022:1

Location:^VARWorkFlowPEP(0,"C91.1",99,1)
001:Emagrecimento
002:3
003:180
004:990
005:0
006:100
007:2
013:(KG)
022:1

Location:^VARWorkFlowPEP(0,"C91.1",100,1)
001:Período
002:3
003:180
004:1000
005:1
006:20
007:0
013:(em meses)
022:1

Location:^VARWorkFlowPEP(0,"C91.1",101,1)
001:Diagnóstico de Anemia Hemolítica Auto-Imune?
002:11
003:5
004:1010
023:0

Location:^VARWorkFlowPEP(0,"C91.1",102,1)
001:Diagnóstico de Trombocitopenia Auto-Imune?
002:11
003:5
004:1020
023:0

Location:^VARWorkFlowPEP(0,"C91.1",103,1)
001:Coombs Direto
002:9
003:101
004:1030
014:Positivo|Negativo
022:1

Location:^VARWorkFlowPEP(0,"C91.1",104,1)
001:105
002:5
003:101
004:1040
005:0
007:1
008:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",105,1)
001:106
002:5
003:101
004:1050
005:0
007:1
008:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",106,1)
001:83
002:5
003:101
004:1060
005:0
007:1
008:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",107,1)
001:104
002:5
003:101
004:1070
005:0
007:1
008:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",108,1)
001:60
002:5
003:101
004:1080
005:0
007:1
008:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",109,1)
001:Anticorpo Anti-Plaquetas
002:9
003:102
004:1090
014:Positivo|Negativo
022:1

Location:^VARWorkFlowPEP(0,"C91.1",110,1)
001:Observações
002:4
003:102
004:1100
011:1000
012:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",111,1)
001:FISH
002:10
003:6
004:1110

Location:^VARWorkFlowPEP(0,"C91.1",112,1)
001:Cariótipo
002:10
003:6
004:900

Location:^VARWorkFlowPEP(0,"C91.1",115,1)
001:Alterações Detectadas
002:9
003:1353
004:1150
014:Ausência de metáfases|Ausência de anormalidades detectadas|Del 17p|Del 11q|Del 13q|Trissomia do cromossomo 12|del(6)(q21q21)|t(11;14)(q13;q32)|t(14;18)(q32;q21)|t(18;22)(q21;q11)|t(2;18)(p11;q21)|t(8;14)(q24;q32)|t(14;22)(q32;q11)|t(4;14)(p16;q32)|Cariótipo complexo (mais do que três alterações)
015:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",121,1)
001:Outras alterações
002:4
003:1353
004:1210
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",122,1)
001:Alterações Detectadas
002:9
003:1352
004:1220
014:Ausência de metáfases|Ausência de anormalidades detectadas (cariótipo normal)|Del 17p|Del 11q|Del 13q|Trissomia do cromossomo 12|del(6)(q21q21)|t(11;14)(q13;q32)|t(14;18)(q32;q21)|t(18;22)(q21;q11)|t(2;18)(p11;q21)|t(8;14)(q24;q32)|t(14;22)(q32;q11)|t(4;14)(p16;q32)|Cariótipo complexo (mais do que três alterações)
015:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",129,1)
001:Outras alterações
002:4
003:1352
004:1290
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",141,1)
001:107
002:12
003:196
004:1410
008:9
017:Obs p/ Mutação em IGVH
022:1

Location:^VARWorkFlowPEP(0,"C91.1",142,1)
001:108
002:12
003:196
004:1420
008:9
017:Mutação detectada
022:1

Location:^VARWorkFlowPEP(0,"C91.1",143,1)
001:109
002:12
003:196
004:1430
008:9
017:Mutação detectada
022:1

Location:^VARWorkFlowPEP(0,"C91.1",144,1)
001:110
002:12
003:196
004:1440
008:9
017:Mutação detectada
022:1

Location:^VARWorkFlowPEP(0,"C91.1",145,1)
001:111
002:12
003:196
004:1450
008:9
017:Mutação detectada
022:1

Location:^VARWorkFlowPEP(0,"C91.1",146,1)
001:112
002:12
003:196
004:1460
008:9
017:Mutação detectada
022:1

Location:^VARWorkFlowPEP(0,"C91.1",147,1)
001:Mutação em Outro gene
002:4
003:196
004:1470
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",155,1)
001:82
002:5
003:7
004:1550
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",156,1)
001:83
002:5
003:7
004:1560
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",157,1)
001:84
002:5
003:7
004:1570
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",158,1)
001:85
002:5
003:7
004:1580
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",159,1)
001:86
002:5
003:7
004:1590
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",160,1)
001:87
002:5
003:7
004:1600
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",161,1)
001:88
002:5
003:7
004:1610
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",162,1)
001:89
002:5
003:7
004:1620
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",163,1)
001:90
002:5
003:7
004:1630
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",164,1)
001:91
002:5
003:7
004:1640
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",165,1)
001:92
002:5
003:7
004:1752
008:3
016:Hepatite C

Location:^VARWorkFlowPEP(0,"C91.1",166,1)
001:93
002:5
003:7
004:1753
008:3
016:Hepatite B

Location:^VARWorkFlowPEP(0,"C91.1",167,1)
001:94
002:5
003:7
004:1754
008:3
016:Hepatite B

Location:^VARWorkFlowPEP(0,"C91.1",168,1)
001:95
002:5
003:7
004:1755
008:3
016:Hepatite B

Location:^VARWorkFlowPEP(0,"C91.1",169,1)
001:96
002:5
003:7
004:1751
008:3
016:HIV

Location:^VARWorkFlowPEP(0,"C91.1",170,1)
001:97
002:5
003:7
004:1700
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",171,1)
001:98
002:5
003:7
004:1710
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",172,1)
001:99
002:5
003:7
004:1720
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",173,1)
001:100
002:5
003:7
004:1730
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",174,1)
001:101
002:5
003:7
004:1740
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",175,1)
001:102
002:5
003:7
004:1750
005:0
007:1
008:1
016:Exames

Location:^VARWorkFlowPEP(0,"C91.1",178,1)
001:Sudorese noturna por pelo menos 1 mês sem evidência de infecção?
002:11
003:1518
004:1780
023:0

Location:^VARWorkFlowPEP(0,"C91.1",179,1)
001:Febre (38 ºC) por pelo menos 2 semanas sem evidência de infeccção?
002:11
003:1518
004:1790
023:0

Location:^VARWorkFlowPEP(0,"C91.1",180,1)
001:Paciente teve emagrecimento (10% do peso em 6 meses)?
002:11
003:1518
004:1800
023:0

Location:^VARWorkFlowPEP(0,"C91.1",181,1)
001:Fadiga acentuada (ECOG >=  2)
002:11
003:1518
004:1810
023:0

Location:^VARWorkFlowPEP(0,"C91.1",185,1)
001:Condição
002:9
003:9
004:1850
014:100% - normal, sem queixas, sem sinais de doença|90% - capaz de atividade normal, poucos sinais ou sintomas de doença|80% - atividade normal com alguma dificuldade, alguns sinais e sintomas|70% - capaz de cuidar de si próprio, incapaz de atividade normal ou trabalho|60% - necessidade de alguma ajuda, capaz de cuidar da maioria das necessidades próprias|50% - frequentemente necessita de ajuda, necessita de atenção médica frequente|40% - incapaz, necessita de cuidado especial e ajuda|30% - gravemente incapaz, admissão hospitalar indicada mas sem risco de morte|20% - muito doente, necessidade de admissão imediata e medidas de suporte ou tratamento|10% - moribundo, rápida progressão para doença fatal|0% - morte.|
016:Karnofsky

Location:^VARWorkFlowPEP(0,"C91.1",186,1)
001:Condição
002:9
003:9
004:1860
014:0 - Assintomático|1 - Sintomático mas completamente ambulatorial|2 - Sintomático, <50% do tempo acamado durante o dia|3 - Sintomático, >50% do tempo acamado durante o dia, não restrito ao leito|4 - Restrito ao leito|5 - Morte|
016:ECOG

Location:^VARWorkFlowPEP(0,"C91.1",187,1)
001:Realizou Mielograma?
002:11
003:37
004:1870
023:1

Location:^VARWorkFlowPEP(0,"C91.1",188,1)
001:Realizou Imunofenotipagem de medula óssea?
002:11
003:38
004:1880
023:1

Location:^VARWorkFlowPEP(0,"C91.1",189,1)
001:Realizou Biopsia de Medula Óssea?
002:11
003:39
004:1890
023:1

Location:^VARWorkFlowPEP(0,"C91.1",192,1)
001:Número de Linfonodos Aumentados
002:3
003:83
004:1920
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",193,1)
001:Número de Linfonodos Aumentados
002:3
003:84
004:1930
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",194,1)
001:Número de Linfonodos Aumentados
002:3
003:85
004:1940
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",196,1)
001:Realizou Análise de Biologia Molecular?
002:11
003:8
004:1960
023:1

Location:^VARWorkFlowPEP(0,"C91.1",197,1)
001:Descrição
002:4
003:7
004:1970
011:1000
012:2
016:Exames Adicionais

Location:^VARWorkFlowPEP(0,"C91.1",198,1)
001:Análise Realizada
002:9
003:196
004:1
014:No Sangue Periférico|Na Medula Óssea
022:1
023:1

Location:^VARWorkFlowPEP(0,"C91.1",199,1)
001:Pré Auricular Esquerdo
002:11
003:73
004:1990
016:Locais com Linfonodos
023:0

Location:^VARWorkFlowPEP(0,"C91.1",200,1)
001:Retro Auricular Esquerdo
002:11
003:73
004:2000
016:Locais com Linfonodos
023:0

Location:^VARWorkFlowPEP(0,"C91.1",201,1)
001:Pré Auricular Direito
002:11
003:73
004:2010
016:Locais com Linfonodos
023:0

Location:^VARWorkFlowPEP(0,"C91.1",202,1)
001:Retro Auricular Direito
002:11
003:73
004:2020
016:Locais com Linfonodos
023:0

Location:^VARWorkFlowPEP(0,"C91.1",203,1)
001:Número de linfonodos aumentados
002:3
003:199
004:2030
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",204,1)
001:Tamanho do maior linfonodo
002:3
003:199
004:2040
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",205,1)
001:Tem doença "Bulky"?
002:11
003:199
004:2050
022:1

Location:^VARWorkFlowPEP(0,"C91.1",206,1)
001:Observações
002:4
003:199
004:2060
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",207,1)
001:Número de linfonodos aumentados
002:3
003:200
004:2070
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",208,1)
001:Número de linfonodos aumentados
002:3
003:201
004:2080
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",209,1)
001:Número de linfonodos aumentados
002:3
003:202
004:2090
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",210,1)
001:Tamanho do maior linfonodo
002:3
003:200
004:2100
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",211,1)
001:Tamanho do maior linfonodo
002:3
003:201
004:2110
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",212,1)
001:Tamanho do maior linfonodo
002:3
003:202
004:2120
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",213,1)
001:Tem doença "Bulky"?
002:11
003:200
004:2130
022:1

Location:^VARWorkFlowPEP(0,"C91.1",214,1)
001:Tem doença "Bulky"?
002:11
003:201
004:2140
022:1

Location:^VARWorkFlowPEP(0,"C91.1",215,1)
001:Tem doença "Bulky"?
002:11
003:202
004:2150
022:1

Location:^VARWorkFlowPEP(0,"C91.1",216,1)
001:Observações
002:4
003:200
004:2160
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",217,1)
001:Observações
002:4
003:201
004:2170
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",218,1)
001:Observações
002:4
003:202
004:2180
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",221,1)
001:Fígado palpável a quantos centimetros do rebordo costal direito?
002:3
003:1350
004:2210
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",222,1)
001:Baço palpável a quantos centimetros do rebordo costal esquerdo?
002:3
003:1351
004:2220
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",223,1)
001:Inguinal Esquerda
002:11
003:245
004:2230
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",224,1)
001:Inguinal Direita
002:11
003:245
004:2240
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",225,1)
001:Número de linfonodos aumentados
002:3
003:223
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",226,1)
001:Número de linfonodos aumentados
002:3
003:224
004:2260
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",227,1)
001:Tamanho do maior linfonodo
002:3
003:223
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",228,1)
001:Tamanho do maior linfonodo
002:3
003:224
004:2280
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",229,1)
001:Tem doença "Bulky"?
002:11
003:223
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",230,1)
001:Tem doença "Bulky"?
002:11
003:224
004:2300
022:1

Location:^VARWorkFlowPEP(0,"C91.1",231,1)
001:Observações
002:4
003:223
004:2310
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",232,1)
001:Observações
002:4
003:224
004:2320
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",233,1)
001:Axilar Esquerda
002:11
003:244
004:2330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",234,1)
001:Axilar Direito
002:11
003:244
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",235,1)
001:Número de linfonodos aumentados
002:3
003:233
004:2350
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",236,1)
001:Número de linfonodos aumentados
002:3
003:234
004:2360
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",237,1)
001:Tamanho do maior linfonodo
002:3
003:233
004:2370
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",238,1)
001:Tamanho do maior linfonodo
002:3
003:234
004:2380
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",239,1)
001:Tem doença "Bulky"?
002:11
003:233
004:2390
022:1

Location:^VARWorkFlowPEP(0,"C91.1",240,1)
001:Tem doença "Bulky"?
002:11
003:234
004:2400
022:1

Location:^VARWorkFlowPEP(0,"C91.1",241,1)
001:Observações
002:4
003:233
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",242,1)
001:Observações
002:4
003:234
004:2420
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",243,1)
001:Paciente Tem Linfonodomegalia na Cervical?
002:11
003:74
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",244,1)
001:Paciente Tem Linfonodomegalia na Região Axilar?
002:11
003:78
004:2440
023:1

Location:^VARWorkFlowPEP(0,"C91.1",245,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:80
004:2450
023:1

Location:^VARWorkFlowPEP(0,"C91.1",253,1)
001:Lado Esquerdo?
002:11
003:859
004:2290
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",255,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:75
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",256,1)
001:Número de linfonodos aumentados
002:3
003:875
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",257,1)
001:Tamanho do maior linfonodo
002:3
003:875
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",258,1)
001:Tem doença "Bulky"?
002:11
003:875
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",259,1)
001:Observações
002:4
003:875
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",261,1)
001:Número de linfonodos aumentados
002:3
003:1370
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",262,1)
001:Tamanho do maior linfonodo
002:3
003:1370
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",263,1)
001:Tem doença "Bulky"?
002:11
003:1370
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",264,1)
001:Observações
002:4
003:1370
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",265,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:77
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",266,1)
001:Número de linfonodos aumentados
002:3
003:881
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",267,1)
001:Tamanho do maior linfonodo
002:3
003:881
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",268,1)
001:Tem doença "Bulky"?
002:11
003:881
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",269,1)
001:Observações
002:4
003:881
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",270,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:79
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",271,1)
001:Número de linfonodos aumentados
002:3
003:887
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",272,1)
001:Tamanho do maior linfonodo
002:3
003:887
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",273,1)
001:Tem doença "Bulky"?
002:11
003:887
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",274,1)
001:Observações
002:4
003:887
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",275,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:81
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",276,1)
001:Número de linfonodos aumentados
002:3
003:893
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",277,1)
001:Tamanho do maior linfonodo
002:3
003:893
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",278,1)
001:Tem doença "Bulky"?
002:11
003:893
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",279,1)
001:Observações
002:4
003:893
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",285,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:71
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",286,1)
001:Número de linfonodos aumentados
002:3
003:285
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",287,1)
001:Tamanho do maior linfonodo
002:3
003:285
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",288,1)
001:Tem doença "Bulky"?
002:11
003:285
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",289,1)
001:Observações
002:4
003:285
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",290,1)
001:1;1
002:7
003:1362
004:2900
022:0

Location:^VARWorkFlowPEP(0,"C91.1",291,1)
001:1;3
002:7
003:1362
004:2910
022:0

Location:^VARWorkFlowPEP(0,"C91.1",292,1)
001:1;6
002:7
003:1362
004:2920
022:0

Location:^VARWorkFlowPEP(0,"C91.1",293,1)
001:1;16
002:7
003:1362
004:2930
022:0

Location:^VARWorkFlowPEP(0,"C91.1",294,1)
001:1;8
002:7
003:1362
004:2940
022:0

Location:^VARWorkFlowPEP(0,"C91.1",295,1)
001:1;7
002:7
003:1362
004:2950
022:0

Location:^VARWorkFlowPEP(0,"C91.1",296,1)
001:1;20
002:7
003:1362
004:2960
022:0

Location:^VARWorkFlowPEP(0,"C91.1",297,1)
001:1;19
002:7
003:1362
004:2970
022:0

Location:^VARWorkFlowPEP(0,"C91.1",298,1)
001:1;10
002:7
003:1362
004:2980
022:0

Location:^VARWorkFlowPEP(0,"C91.1",299,1)
001:1;11
002:7
003:1362
004:2990
022:0

Location:^VARWorkFlowPEP(0,"C91.1",300,1)
001:1;15
002:7
003:1362
004:3000
022:0

Location:^VARWorkFlowPEP(0,"C91.1",301,1)
001:1;17
002:7
003:1362
004:3010
022:0

Location:^VARWorkFlowPEP(0,"C91.1",302,1)
001:1;9
002:7
003:1362
004:3020
022:0

Location:^VARWorkFlowPEP(0,"C91.1",303,1)
001:1;5
002:7
003:1362
004:3030
022:0

Location:^VARWorkFlowPEP(0,"C91.1",304,1)
001:1;4
002:7
003:1362
004:3040
022:0

Location:^VARWorkFlowPEP(0,"C91.1",305,1)
001:1;2
002:7
003:1362
004:3050
022:0

Location:^VARWorkFlowPEP(0,"C91.1",306,1)
001:1;22
002:7
003:1362
004:3060
022:0

Location:^VARWorkFlowPEP(0,"C91.1",307,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:290
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",308,1)
001:Número de linfonodos aumentados
002:3
003:307
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",309,1)
001:Tamanho do maior linfonodo
002:3
003:307
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",310,1)
001:Tem doença "Bulky"?
002:11
003:307
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",311,1)
001:Observações
002:4
003:307
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",312,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:291
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",313,1)
001:Número de linfonodos aumentados
002:3
003:1520
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",314,1)
001:Tamanho do maior linfonodo
002:3
003:1520
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",315,1)
001:Tem doença "Bulky"?
002:11
003:1520
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",316,1)
001:Observações
002:4
003:1520
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",317,1)
001:Submandibular Esquerdo?
002:11
003:1686
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",318,1)
001:Número de linfonodos aumentados
002:3
003:317
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",319,1)
001:Tamanho do maior linfonodo
002:3
003:317
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",320,1)
001:Tem doença "Bulky"?
002:11
003:317
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",321,1)
001:Observações
002:4
003:317
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",322,1)
001:Peitoral Esquerdo
002:11
003:1581
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",323,1)
001:Número de linfonodos aumentados
002:3
003:322
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",324,1)
001:Tamanho do maior linfonodo
002:3
003:322
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",325,1)
001:Tem doença "Bulky"?
002:11
003:322
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",326,1)
001:Observações
002:4
003:322
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",327,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:294
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",328,1)
001:Número de linfonodos aumentados
002:3
003:1429
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",329,1)
001:Tamanho do maior linfonodo
002:3
003:1429
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",330,1)
001:Tem doença "Bulky"?
002:11
003:1429
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",331,1)
001:Observações
002:4
003:1429
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",332,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:295
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",333,1)
001:Número de linfonodos aumentados
002:3
003:899
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",334,1)
001:Tamanho do maior linfonodo
002:3
003:899
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",335,1)
001:Tem doença "Bulky"?
002:11
003:899
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",336,1)
001:Observações
002:4
003:899
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",337,1)
001:Paciente tem esplenomegalia?
002:11
003:296
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",339,1)
001:Tamanho do baço
002:3
003:337
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",342,1)
001:Paciente tem hepatomegalia?
002:11
003:297
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",344,1)
001:Volume do fígado
002:3
003:342
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",347,1)
001:Inguinal Esquerdo
002:11
003:1567
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",348,1)
001:Número de linfonodos aumentados
002:3
003:347
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",349,1)
001:Tamanho do maior linfonodo
002:3
003:347
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",350,1)
001:Tem doença "Bulky"?
002:11
003:347
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",351,1)
001:Observações
002:4
003:347
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",352,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:299
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",353,1)
001:Número de linfonodos aumentados
002:3
003:905
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",354,1)
001:Tamanho do maior linfonodo
002:3
003:905
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",355,1)
001:Tem doença "Bulky"?
002:11
003:905
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",356,1)
001:Observações
002:4
003:905
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",357,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:300
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",362,1)
001:Para-aórtico Esquerdo?
002:11
003:1575
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",363,1)
001:Número de linfonodos aumentados
002:3
003:362
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",364,1)
001:Tamanho do maior linfonodo
002:3
003:362
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",365,1)
001:Tem doença "Bulky"?
002:11
003:362
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",366,1)
001:Observações
002:4
003:362
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",367,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:302
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",368,1)
001:Número de linfonodos aumentados
002:3
003:911
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",369,1)
001:Tamanho do maior linfonodo
002:3
003:911
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",370,1)
001:Tem doença "Bulky"?
002:11
003:911
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",371,1)
001:Observações
002:4
003:911
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",372,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:303
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",373,1)
001:Número de linfonodos aumentados
002:3
003:917
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",374,1)
001:Tamanho do maior linfonodo
002:3
003:917
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",375,1)
001:Tem doença "Bulky"?
002:11
003:917
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",376,1)
001:Observações
002:4
003:917
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",377,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:304
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",378,1)
001:Número de linfonodos aumentados
002:3
003:1536
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",379,1)
001:Tamanho do maior linfonodo
002:3
003:1536
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",380,1)
001:Tem doença "Bulky"?
002:11
003:1536
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",381,1)
001:Observações
002:4
003:1536
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",387,1)
001:Mesentérico Esquerdo
002:11
003:1569
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",388,1)
001:Número de linfonodos aumentados
002:3
003:387
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",389,1)
001:Tamanho do maior linfonodo
002:3
003:387
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",390,1)
001:Tem doença "Bulky"?
002:11
003:387
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",391,1)
001:Observações
002:4
003:387
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",392,1)
001:Relação G/E
002:3
003:41
004:420
005:0
007:1
022:0

Location:^VARWorkFlowPEP(0,"C91.1",393,1)
001:Análise Realizada
002:9
003:1353
004:1100
014:No Sangue Periférico|Na Medula Óssea
022:1
023:1

Location:^VARWorkFlowPEP(0,"C91.1",394,1)
001:Análise Realizada
002:9
003:1352
004:1200
014:No Sangue Periférico|Na Medula Óssea
022:1
023:1

Location:^VARWorkFlowPEP(0,"C91.1",395,1)
001:113
002:5
003:66
004:544
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",396,1)
001:114
002:5
003:66
004:545
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",397,1)
001:115
002:5
003:66
004:546
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",398,1)
001:116
002:5
003:66
004:547
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",399,1)
001:117
002:5
003:66
004:550
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",400,1)
001:118
002:5
003:66
004:552
008:10
016:Fenótipo dos linfócitos infiltrando medula óssea
022:1

Location:^VARWorkFlowPEP(0,"C91.1",401,1)
001:75
002:5
003:871
004:4010
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",402,1)
001:76
002:5
003:871
004:4020
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",403,1)
001:77
002:5
003:871
004:4030
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",404,1)
001:113
002:5
003:871
004:4040
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",405,1)
001:114
002:5
003:871
004:4050
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",406,1)
001:115
002:5
003:871
004:4060
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",407,1)
001:116
002:5
003:871
004:4070
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",408,1)
001:81
002:5
003:871
004:4080
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",409,1)
001:117
002:5
003:871
004:4090
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",410,1)
001:80
002:5
003:871
004:4100
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",411,1)
001:118
002:5
003:871
004:4110
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",412,1)
001:Porcentagem de linfócitos com<br>fenótipos selecionados na medula óssea
002:3
003:871
004:4120
005:0
006:100
007:1
013:% dos linfócitos
022:1

Location:^VARWorkFlowPEP(0,"C91.1",440,1)
001:74
002:5
003:444
004:4400
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",441,1)
001:75
002:5
003:444
004:4410
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",442,1)
001:76
002:5
003:444
004:4420
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",443,1)
001:77
002:5
003:444
004:4430
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",444,1)
001:Outro Fenótipo?
002:11
003:1369
004:4440
022:1

Location:^VARWorkFlowPEP(0,"C91.1",445,1)
001:113
002:5
003:444
004:4450
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",446,1)
001:114
002:5
003:444
004:4460
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",447,1)
001:115
002:5
003:444
004:4470
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",448,1)
001:116
002:5
003:444
004:4480
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",449,1)
001:81
002:5
003:444
004:4490
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",450,1)
001:117
002:5
003:444
004:4500
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",451,1)
001:80
002:5
003:444
004:4510
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",452,1)
001:118
002:5
003:444
004:4520
008:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",453,1)
001:Quantidade absoluta de células com fenótipos<br>selecionados no sangue periférico
002:3
003:444
004:4530
005:0
007:1
013:/ul
022:1

Location:^VARWorkFlowPEP(0,"C91.1",454,1)
001:Porcentagem de linfócitos com<br>fenótipos selecionadosna medula óssea
002:3
003:444
004:4540
005:0
006:100
007:1
013:% dos linfócitos
022:1

Location:^VARWorkFlowPEP(0,"C91.1",455,1)
001:O paciente tem outra causa para anemia ou<br>trombocitopenia que não seja LLC?
002:11
003:5
004:4550
023:0

Location:^VARWorkFlowPEP(0,"C91.1",456,1)
001:TC
002:10
003:3
004:4560

Location:^VARWorkFlowPEP(0,"C91.1",457,1)
001:RM
002:10
003:3
004:4570

Location:^VARWorkFlowPEP(0,"C91.1",458,1)
001:RX
002:10
003:3
004:4580

Location:^VARWorkFlowPEP(0,"C91.1",459,1)
001:PET CT
002:10
003:3
004:4590

Location:^VARWorkFlowPEP(0,"C91.1",460,1)
001:Ultrassonografia
002:10
003:3
004:4600

Location:^VARWorkFlowPEP(0,"C91.1",461,1)
001:Informações Clínicas
002:10
003:4
004:4610

Location:^VARWorkFlowPEP(0,"C91.1",462,1)
001:1;1
002:7
003:1363
004:2900
022:0

Location:^VARWorkFlowPEP(0,"C91.1",463,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:462
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",464,1)
001:Número de linfonodos aumentados
002:3
003:463
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",465,1)
001:Tamanho do maior linfonodo
002:3
003:463
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",466,1)
001:Tem doença "Bulky"?
002:11
003:463
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",467,1)
001:Observações
002:4
003:463
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",468,1)
001:1;3
002:7
003:1363
004:2910
022:0

Location:^VARWorkFlowPEP(0,"C91.1",474,1)
001:1;6
002:7
003:1363
004:2920
022:0

Location:^VARWorkFlowPEP(0,"C91.1",475,1)
001:Submandibular Esquerdo?
002:11
003:1685
004:2430
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",476,1)
001:Número de linfonodos aumentados
002:3
003:475
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",477,1)
001:Tamanho do maior linfonodo
002:3
003:475
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",478,1)
001:Tem doença "Bulky"?
002:11
003:475
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",479,1)
001:Observações
002:4
003:475
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",480,1)
001:1;16
002:7
003:1363
004:2930
022:0

Location:^VARWorkFlowPEP(0,"C91.1",486,1)
001:1;8
002:7
003:1363
004:2940
022:0

Location:^VARWorkFlowPEP(0,"C91.1",487,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:486
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",488,1)
001:Número de linfonodos aumentados
002:3
003:1431
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",489,1)
001:Tamanho do maior linfonodo
002:3
003:1431
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",490,1)
001:Tem doença "Bulky"?
002:11
003:1431
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",491,1)
001:Observações
002:4
003:1431
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",492,1)
001:1;7
002:7
003:1363
004:2950
022:0

Location:^VARWorkFlowPEP(0,"C91.1",493,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:492
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",494,1)
001:Número de linfonodos aumentados
002:3
003:923
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",495,1)
001:Tamanho do maior linfonodo
002:3
003:923
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",496,1)
001:Tem doença "Bulky"?
002:11
003:923
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",497,1)
001:Observações
002:4
003:923
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",498,1)
001:1;20
002:7
003:1363
004:2960
022:0

Location:^VARWorkFlowPEP(0,"C91.1",499,1)
001:Paciente tem esplenomegalia?
002:11
003:498
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",501,1)
001:Tamanho do baço
002:3
003:499
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",504,1)
001:1;19
002:7
003:1363
004:2970
022:0

Location:^VARWorkFlowPEP(0,"C91.1",505,1)
001:Paciente tem hepatomegalia?
002:11
003:504
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",507,1)
001:Volume do fígado
002:3
003:505
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",510,1)
001:1;10
002:7
003:1363
004:2980
022:0

Location:^VARWorkFlowPEP(0,"C91.1",516,1)
001:1;11
002:7
003:1363
004:2990
022:0

Location:^VARWorkFlowPEP(0,"C91.1",517,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:516
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",518,1)
001:Número de linfonodos aumentados
002:3
003:929
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",519,1)
001:Tamanho do maior linfonodo
002:3
003:929
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",520,1)
001:Tem doença "Bulky"?
002:11
003:929
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",521,1)
001:Observações
002:4
003:929
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",522,1)
001:1;15
002:7
003:1363
004:3000
022:0

Location:^VARWorkFlowPEP(0,"C91.1",528,1)
001:1;17
002:7
003:1363
004:3010
022:0

Location:^VARWorkFlowPEP(0,"C91.1",534,1)
001:1;9
002:7
003:1363
004:3020
022:0

Location:^VARWorkFlowPEP(0,"C91.1",535,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:534
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",536,1)
001:Número de linfonodos aumentados
002:3
003:935
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",537,1)
001:Tamanho do maior linfonodo
002:3
003:935
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",538,1)
001:Tem doença "Bulky"?
002:11
003:935
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",539,1)
001:Observações
002:4
003:935
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",540,1)
001:1;5
002:7
003:1363
004:3030
022:0

Location:^VARWorkFlowPEP(0,"C91.1",541,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:540
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",542,1)
001:Número de linfonodos aumentados
002:3
003:941
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",543,1)
001:Tamanho do maior linfonodo
002:3
003:941
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",544,1)
001:Tem doença "Bulky"?
002:11
003:941
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",545,1)
001:Observações
002:4
003:941
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",546,1)
001:1;4
002:7
003:1363
004:3040
022:0

Location:^VARWorkFlowPEP(0,"C91.1",552,1)
001:1;2
002:7
003:1363
004:3050
022:0

Location:^VARWorkFlowPEP(0,"C91.1",558,1)
001:1;22
002:7
003:1363
004:3060
022:0

Location:^VARWorkFlowPEP(0,"C91.1",666,1)
001:1;1
002:7
003:1365
004:2900
022:0

Location:^VARWorkFlowPEP(0,"C91.1",667,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:666
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",668,1)
001:Número de linfonodos aumentados
002:3
003:667
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",669,1)
001:Tamanho do maior linfonodo
002:3
003:667
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",670,1)
001:Tem doença "Bulky"?
002:11
003:667
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",671,1)
001:Observações
002:4
003:667
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",672,1)
001:1;3
002:7
003:1365
004:2910
022:0

Location:^VARWorkFlowPEP(0,"C91.1",678,1)
001:1;6
002:7
003:1365
004:2920
022:0

Location:^VARWorkFlowPEP(0,"C91.1",679,1)
001:Submandibular Esquerdo?
002:11
003:1882
004:2430
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",680,1)
001:Número de linfonodos aumentados
002:3
003:679
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",681,1)
001:Tamanho do maior linfonodo
002:3
003:679
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",682,1)
001:Tem doença "Bulky"?
002:11
003:679
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",683,1)
001:Observações
002:4
003:679
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",684,1)
001:1;16
002:7
003:1365
004:2930
022:0

Location:^VARWorkFlowPEP(0,"C91.1",690,1)
001:1;8
002:7
003:1365
004:2940
022:0

Location:^VARWorkFlowPEP(0,"C91.1",691,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:690
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",692,1)
001:Número de linfonodos aumentados
002:3
003:1433
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",693,1)
001:Tamanho do maior linfonodo
002:3
003:1433
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",694,1)
001:Tem doença "Bulky"?
002:11
003:1433
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",695,1)
001:Observações
002:4
003:1433
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",696,1)
001:1;7
002:7
003:1365
004:2950
022:0

Location:^VARWorkFlowPEP(0,"C91.1",697,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:696
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",698,1)
001:Número de linfonodos aumentados
002:3
003:971
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",699,1)
001:Tamanho do maior linfonodo
002:3
003:971
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",700,1)
001:Tem doença "Bulky"?
002:11
003:971
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",701,1)
001:Observações
002:4
003:971
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",702,1)
001:1;20
002:7
003:1365
004:2960
022:0

Location:^VARWorkFlowPEP(0,"C91.1",703,1)
001:Paciente tem esplenomegalia?
002:11
003:702
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",705,1)
001:Tamanho do baço
002:3
003:703
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",708,1)
001:1;19
002:7
003:1365
004:2970
022:0

Location:^VARWorkFlowPEP(0,"C91.1",709,1)
001:Paciente tem hepatomegalia?
002:11
003:708
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",711,1)
001:Volume do fígado
002:3
003:709
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",714,1)
001:1;10
002:7
003:1365
004:2980
022:0

Location:^VARWorkFlowPEP(0,"C91.1",720,1)
001:1;11
002:7
003:1365
004:2990
022:0

Location:^VARWorkFlowPEP(0,"C91.1",721,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:720
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",722,1)
001:Número de linfonodos aumentados
002:3
003:977
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",723,1)
001:Tamanho do maior linfonodo
002:3
003:977
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",724,1)
001:Tem doença "Bulky"?
002:11
003:977
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",725,1)
001:Observações
002:4
003:977
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",726,1)
001:1;15
002:7
003:1365
004:3000
022:0

Location:^VARWorkFlowPEP(0,"C91.1",732,1)
001:1;17
002:7
003:1365
004:3010
022:0

Location:^VARWorkFlowPEP(0,"C91.1",738,1)
001:1;9
002:7
003:1365
004:3020
022:0

Location:^VARWorkFlowPEP(0,"C91.1",739,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:738
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",740,1)
001:Número de linfonodos aumentados
002:3
003:983
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",741,1)
001:Tamanho do maior linfonodo
002:3
003:983
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",742,1)
001:Tem doença "Bulky"?
002:11
003:983
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",743,1)
001:Observações
002:4
003:983
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",744,1)
001:1;5
002:7
003:1365
004:3030
022:0

Location:^VARWorkFlowPEP(0,"C91.1",745,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:744
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",746,1)
001:Número de linfonodos aumentados
002:3
003:989
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",747,1)
001:Tamanho do maior linfonodo
002:3
003:989
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",748,1)
001:Tem doença "Bulky"?
002:11
003:989
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",749,1)
001:Observações
002:4
003:989
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",750,1)
001:1;4
002:7
003:1365
004:3040
022:0

Location:^VARWorkFlowPEP(0,"C91.1",756,1)
001:1;2
002:7
003:1365
004:3050
022:0

Location:^VARWorkFlowPEP(0,"C91.1",762,1)
001:1;22
002:7
003:1365
004:3060
022:0

Location:^VARWorkFlowPEP(0,"C91.1",768,1)
001:1;1
002:7
003:1366
004:2900
022:0

Location:^VARWorkFlowPEP(0,"C91.1",769,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:768
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",770,1)
001:Número de linfonodos aumentados
002:3
003:769
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",771,1)
001:Tamanho do maior linfonodo
002:3
003:769
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",772,1)
001:Tem doença "Bulky"?
002:11
003:769
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",773,1)
001:Observações
002:4
003:769
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",774,1)
001:1;3
002:7
003:1366
004:2910
022:0

Location:^VARWorkFlowPEP(0,"C91.1",780,1)
001:1;6
002:7
003:1366
004:2920
022:0

Location:^VARWorkFlowPEP(0,"C91.1",781,1)
001:Submandibular Esquerdo?
002:11
003:1883
004:2430
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",782,1)
001:Número de linfonodos aumentados
002:3
003:781
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",783,1)
001:Tamanho do maior linfonodo
002:3
003:781
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",784,1)
001:Tem doença "Bulky"?
002:11
003:781
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",785,1)
001:Observações
002:4
003:781
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",786,1)
001:1;16
002:7
003:1366
004:2930
022:0

Location:^VARWorkFlowPEP(0,"C91.1",792,1)
001:1;8
002:7
003:1366
004:2940
022:0

Location:^VARWorkFlowPEP(0,"C91.1",793,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:792
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",794,1)
001:Número de linfonodos aumentados
002:3
003:1435
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",795,1)
001:Tamanho do maior linfonodo
002:3
003:1435
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",796,1)
001:Tem doença "Bulky"?
002:11
003:1435
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",797,1)
001:Observações
002:4
003:1435
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",798,1)
001:1;7
002:7
003:1366
004:2950
022:0

Location:^VARWorkFlowPEP(0,"C91.1",799,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:798
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",800,1)
001:Número de linfonodos aumentados
002:3
003:995
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",801,1)
001:Tamanho do maior linfonodo
002:3
003:995
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",802,1)
001:Tem doença "Bulky"?
002:11
003:995
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",803,1)
001:Observações
002:4
003:995
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",804,1)
001:1;20
002:7
003:1366
004:2960
022:0

Location:^VARWorkFlowPEP(0,"C91.1",805,1)
001:Paciente tem esplenomegalia?
002:11
003:804
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",807,1)
001:Tamanho do baço
002:3
003:805
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",810,1)
001:1;19
002:7
003:1366
004:2970
022:0

Location:^VARWorkFlowPEP(0,"C91.1",811,1)
001:Paciente tem hepatomegalia?
002:11
003:810
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",813,1)
001:Volume do fígado
002:3
003:811
004:2270
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",816,1)
001:1;10
002:7
003:1366
004:2980
022:0

Location:^VARWorkFlowPEP(0,"C91.1",822,1)
001:1;11
002:7
003:1366
004:2990
022:0

Location:^VARWorkFlowPEP(0,"C91.1",823,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:822
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",824,1)
001:Número de linfonodos aumentados
002:3
003:1001
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",825,1)
001:Tamanho do maior linfonodo
002:3
003:1001
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",826,1)
001:Tem doença "Bulky"?
002:11
003:1001
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",827,1)
001:Observações
002:4
003:1001
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",828,1)
001:1;15
002:7
003:1366
004:3000
022:0

Location:^VARWorkFlowPEP(0,"C91.1",834,1)
001:1;17
002:7
003:1366
004:3010
022:0

Location:^VARWorkFlowPEP(0,"C91.1",840,1)
001:1;9
002:7
003:1366
004:3020
022:0

Location:^VARWorkFlowPEP(0,"C91.1",841,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:840
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",842,1)
001:Número de linfonodos aumentados
002:3
003:1007
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",843,1)
001:Tamanho do maior linfonodo
002:3
003:1007
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",844,1)
001:Tem doença "Bulky"?
002:11
003:1007
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",845,1)
001:Observações
002:4
003:1007
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",846,1)
001:1;5
002:7
003:1366
004:3030
022:0

Location:^VARWorkFlowPEP(0,"C91.1",847,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:846
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",848,1)
001:Número de linfonodos aumentados
002:3
003:1013
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",849,1)
001:Tamanho do maior linfonodo
002:3
003:1013
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",850,1)
001:Tem doença "Bulky"?
002:11
003:1013
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",851,1)
001:Observações
002:4
003:1013
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",852,1)
001:1;4
002:7
003:1366
004:3040
022:0

Location:^VARWorkFlowPEP(0,"C91.1",858,1)
001:1;2
002:7
003:1366
004:3050
022:0

Location:^VARWorkFlowPEP(0,"C91.1",859,1)
001:Acometimento de tonsilas palatinas?
002:11
003:1454
004:2430
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",864,1)
001:1;22
002:7
003:1366
004:3060
022:0

Location:^VARWorkFlowPEP(0,"C91.1",871,1)
001:Outro Fenótipo?
002:11
003:188
004:8710
022:1

Location:^VARWorkFlowPEP(0,"C91.1",872,1)
001:Porcentagem dos linfócitos com fenótipo<br>CD19+/CD5+/CD23+ na medula óssea
002:3
003:188
004:400
005:0
006:100
007:1
013:% dos linfócitos
022:1

Location:^VARWorkFlowPEP(0,"C91.1",873,1)
001:Outros
002:1
003:69
004:8730
022:1

Location:^VARWorkFlowPEP(0,"C91.1",874,1)
001:Descrição
002:4
003:873
004:8740
011:1000
012:7

Location:^VARWorkFlowPEP(0,"C91.1",875,1)
001:Supraclavicular Esquerdo
002:11
003:255
004:2330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",876,1)
001:Supraclavicular Direito
002:11
003:255
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",877,1)
001:Número de linfonodos aumentados
002:3
003:876
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",878,1)
001:Tamanho do maior linfonodo
002:3
003:876
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",879,1)
001:Tem doença "Bulky"?
002:11
003:876
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",880,1)
001:Observações
002:4
003:876
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",881,1)
001:Epitroclear Esquerdo
002:11
003:265
004:2330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",882,1)
001:Epitroclear Direito
002:11
003:265
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",883,1)
001:Número de linfonodos aumentados
002:3
003:882
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",884,1)
001:Tamanho do maior linfonodo
002:3
003:882
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",885,1)
001:Tem doença "Bulky"?
002:11
003:882
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",886,1)
001:Observações
002:4
003:882
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",887,1)
001:Braquial Esquerdo
002:11
003:270
004:2330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",888,1)
001:Braquial Direito
002:11
003:270
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",889,1)
001:Número de linfonodos aumentados
002:3
003:888
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",890,1)
001:Tamanho do maior linfonodo
002:3
003:888
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",891,1)
001:Tem doença "Bulky"?
002:11
003:888
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",892,1)
001:Observações
002:4
003:888
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",893,1)
001:Poplíteo Esquerdo
002:11
003:275
004:2330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",894,1)
001:Poplíteo Direito
002:11
003:275
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",895,1)
001:Número de linfonodos aumentados
002:3
003:894
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",896,1)
001:Tamanho do maior linfonodo
002:3
003:894
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",897,1)
001:Tem doença "Bulky"?
002:11
003:894
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",898,1)
001:Observações
002:4
003:894
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",899,1)
001:Epitroclear Esquerdo
002:11
003:332
004:2330
022:1

Location:^VARWorkFlowPEP(0,"C91.1",900,1)
001:Epitroclear Direito
002:11
003:332
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",901,1)
001:Número de linfonodos aumentados
002:3
003:900
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",902,1)
001:Tamanho do maior linfonodo
002:3
003:900
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",903,1)
001:Tem doença "Bulky"?
002:11
003:900
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",904,1)
001:Observações
002:4
003:900
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",905,1)
001:Poplíteo Esquerdo
002:11
003:352
004:2330
022:1

Location:^VARWorkFlowPEP(0,"C91.1",906,1)
001:Poplíteo Direito
002:11
003:352
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",907,1)
001:Número de linfonodos aumentados
002:3
003:906
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",908,1)
001:Tamanho do maior linfonodo
002:3
003:906
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",909,1)
001:Tem doença "Bulky"?
002:11
003:906
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",910,1)
001:Observações
002:4
003:906
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",911,1)
001:Braquial Esquerdo
002:11
003:367
004:2330
022:1

Location:^VARWorkFlowPEP(0,"C91.1",912,1)
001:Braquial Direito
002:11
003:367
004:2340
022:1

Location:^VARWorkFlowPEP(0,"C91.1",913,1)
001:Número de linfonodos aumentados
002:3
003:912
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",914,1)
001:Tamanho do maior linfonodo
002:3
003:912
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",915,1)
001:Tem doença "Bulky"?
002:11
003:912
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",916,1)
001:Observações
002:4
003:912
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",917,1)
001:Supraclavicular Esquerdo
002:11
003:372
004:2330
022:1

Location:^VARWorkFlowPEP(0,"C91.1",918,1)
001:Supraclavicular Direito
002:11
003:372
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",919,1)
001:Número de linfonodos aumentados
002:3
003:918
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",920,1)
001:Tamanho do maior linfonodo
002:3
003:918
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",921,1)
001:Tem doença "Bulky"?
002:11
003:918
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",922,1)
001:Observações
002:4
003:918
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",923,1)
001:Epitroclear Esquerdo
002:11
003:493
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",924,1)
001:Epitroclear Direito
002:11
003:493
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",925,1)
001:Número de linfonodos aumentados
002:3
003:924
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",926,1)
001:Tamanho do maior linfonodo
002:3
003:924
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",927,1)
001:Tem doença "Bulky"?
002:11
003:924
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",928,1)
001:Observações
002:4
003:924
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",929,1)
001:Poplíteo Esquerdo
002:11
003:517
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",930,1)
001:Poplíteo Direito
002:11
003:517
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",931,1)
001:Número de linfonodos aumentados
002:3
003:930
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",932,1)
001:Tamanho do maior linfonodo
002:3
003:930
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",933,1)
001:Tem doença "Bulky"?
002:11
003:930
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",934,1)
001:Observações
002:4
003:930
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",935,1)
001:Braquial Esquerdo
002:11
003:535
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",936,1)
001:Braquial Direito
002:11
003:535
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",937,1)
001:Número de linfonodos aumentados
002:3
003:936
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",938,1)
001:Tamanho do maior linfonodo
002:3
003:936
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",939,1)
001:Tem doença "Bulky"?
002:11
003:936
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",940,1)
001:Observações
002:4
003:936
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",941,1)
001:Supraclavicular Esquerdo
002:11
003:541
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",942,1)
001:Supraclavicular Direito
002:11
003:541
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",943,1)
001:Número de linfonodos aumentados
002:3
003:942
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",944,1)
001:Tamanho do maior linfonodo
002:3
003:942
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",945,1)
001:Tem doença "Bulky"?
002:11
003:942
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",946,1)
001:Observações
002:4
003:942
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",971,1)
001:Epitroclear Esquerdo
002:11
003:697
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",972,1)
001:Epitroclear Direito
002:11
003:697
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",973,1)
001:Número de linfonodos aumentados
002:3
003:972
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",974,1)
001:Tamanho do maior linfonodo
002:3
003:972
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",975,1)
001:Tem doença "Bulky"?
002:11
003:972
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",976,1)
001:Observações
002:4
003:972
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",977,1)
001:Poplíteo Esquerdo
002:11
003:721
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",978,1)
001:Poplíteo Direito
002:11
003:721
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",979,1)
001:Número de linfonodos aumentados
002:3
003:978
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",980,1)
001:Tamanho do maior linfonodo
002:3
003:978
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",981,1)
001:Tem doença "Bulky"?
002:11
003:978
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",982,1)
001:Observações
002:4
003:978
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",983,1)
001:Braquial Esquerdo
002:11
003:739
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",984,1)
001:Braquial Direito
002:11
003:739
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",985,1)
001:Número de linfonodos aumentados
002:3
003:984
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",986,1)
001:Tamanho do maior linfonodo
002:3
003:984
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",987,1)
001:Tem doença "Bulky"?
002:11
003:984
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",988,1)
001:Observações
002:4
003:984
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",989,1)
001:Supraclavicular Esquerdo
002:11
003:745
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",990,1)
001:Supraclavicular Direito
002:11
003:745
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",991,1)
001:Número de linfonodos aumentados
002:3
003:990
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",992,1)
001:Tamanho do maior linfonodo
002:3
003:990
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",993,1)
001:Tem doença "Bulky"?
002:11
003:990
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",994,1)
001:Observações
002:4
003:990
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",995,1)
001:Epitroclear Esquerdo
002:11
003:799
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",996,1)
001:Epitroclear Direito
002:11
003:799
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",997,1)
001:Número de linfonodos aumentados
002:3
003:996
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",998,1)
001:Tamanho do maior linfonodo
002:3
003:996
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",999,1)
001:Tem doença "Bulky"?
002:11
003:996
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1000,1)
001:Observações
002:4
003:996
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1001,1)
001:Poplíteo Esquerdo
002:11
003:823
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",1002,1)
001:Poplíteo Direito
002:11
003:823
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1003,1)
001:Número de linfonodos aumentados
002:3
003:1002
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1004,1)
001:Tamanho do maior linfonodo
002:3
003:1002
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1005,1)
001:Tem doença "Bulky"?
002:11
003:1002
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1006,1)
001:Observações
002:4
003:1002
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1007,1)
001:Braquial Esquerdo
002:11
003:841
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",1008,1)
001:Braquial Direito
002:11
003:841
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1009,1)
001:Número de linfonodos aumentados
002:3
003:1008
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1010,1)
001:Tamanho do maior linfonodo
002:3
003:1008
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1011,1)
001:Tem doença "Bulky"?
002:11
003:1008
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1012,1)
001:Observações
002:4
003:1008
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1013,1)
001:Supraclavicular Esquerdo
002:11
003:847
004:2330
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",1014,1)
001:Supraclavicular Direito
002:11
003:847
004:2340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1015,1)
001:Número de linfonodos aumentados
002:3
003:1014
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1016,1)
001:Tamanho do maior linfonodo
002:3
003:1014
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1017,1)
001:Tem doença "Bulky"?
002:11
003:1014
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1018,1)
001:Observações
002:4
003:1014
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1019,1)
001:Outros
002:8
003:1362
004:10190
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1020,1)
001:Outros
002:1
003:1363
004:10200
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1022,1)
001:Outros
002:1
003:1365
004:10220
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1023,1)
001:Outros
002:1
003:1366
004:10230
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1024,1)
001:Descrição
002:4
003:1019
004:10240
011:1000
012:7

Location:^VARWorkFlowPEP(0,"C91.1",1025,1)
001:Descrição
002:4
003:1020
004:10250
011:1000
012:7

Location:^VARWorkFlowPEP(0,"C91.1",1026,1)
001:Resultado
002:4
003:1364
004:10260
011:1000
012:7
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1027,1)
001:Outros
002:4
003:1022
004:10270
011:1000
012:7

Location:^VARWorkFlowPEP(0,"C91.1",1028,1)
001:Descrição
002:4
003:1023
004:10280
011:1000
012:7

Location:^VARWorkFlowPEP(0,"C91.1",1029,1)
001:Maior captação
002:3
003:971
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1030,1)
001:Maior captação
002:3
003:977
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1031,1)
001:Maior captação
002:3
003:983
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1032,1)
001:Maior captação
002:3
003:989
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1033,1)
001:Maior captação
002:3
003:972
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1034,1)
001:Maior captação
002:3
003:978
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1035,1)
001:Maior captação
002:3
003:984
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1036,1)
001:Maior captação
002:3
003:990
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1037,1)
001:Maior captação
002:3
003:667
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1039,1)
001:Maior captação
002:3
003:679
004:2400
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1041,1)
001:Maior captação
002:3
003:1433
004:2300
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1048,1)
001:Data de Realização dos Exames
002:13
003:11
004:1

Location:^VARWorkFlowPEP(0,"C91.1",1049,1)
001:Data dos Exames
002:13
003:7
004:1

Location:^VARWorkFlowPEP(0,"C91.1",1050,1)
001:Acometimento de tonsilas linguais?
002:11
003:1454
004:10500
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1051,1)
001:Acometimento de tonsilas nasofaríngea?
002:11
003:1454
004:10510
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1052,1)
001:Lado Direito?
002:11
003:859
004:10520
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1053,1)
001:Tamanho
002:3
003:253
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1054,1)
001:Tamanho
002:3
003:1052
004:10540
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1055,1)
001:Lado Esquerdo?
002:11
003:1050
004:10550
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1056,1)
001:Lado Direito?
002:11
003:1050
004:10560
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1057,1)
001:Lado Esquerdo?
002:11
003:1051
004:10570
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1058,1)
001:Lado Direito?
002:11
003:1051
004:10580
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1059,1)
001:Tamanho
002:3
003:1055
004:10590
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1060,1)
001:Tamanho
002:3
003:1056
004:10600
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1061,1)
001:Tamanho
002:3
003:1057
004:10610
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1062,1)
001:Tamanho
002:3
003:1058
004:10620
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1063,1)
001:Outro
002:11
003:1454
004:10630
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1064,1)
001:Descrição
002:4
003:1063
004:10640
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1065,1)
001:Acometimento de tonsilas palatinas?
002:11
003:305
004:2430

Location:^VARWorkFlowPEP(0,"C91.1",1066,1)
001:Lado Direito?
002:11
003:1065
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1067,1)
001:Tamanho
002:3
003:1066
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1068,1)
001:Lado Esquerdo?
002:11
003:1065
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1069,1)
001:Tamanho
002:3
003:1068
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1070,1)
001:Acometimento de tonsilas linguais?
002:11
003:305
004:10500

Location:^VARWorkFlowPEP(0,"C91.1",1071,1)
001:Lado Direito?
002:11
003:1070
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1072,1)
001:Tamanho
002:3
003:1071
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1073,1)
001:Lado Esquerdo?
002:11
003:1070
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1074,1)
001:Tamanho
002:3
003:1073
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1075,1)
001:Acometimento de tonsilas naosfaríngea?
002:11
003:305
004:10510

Location:^VARWorkFlowPEP(0,"C91.1",1076,1)
001:Lado Direito?
002:11
003:1075
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1077,1)
001:Tamanho
002:3
003:1076
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1078,1)
001:Lado Esquerdo?
002:11
003:1075
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1079,1)
001:Tamanho
002:3
003:1078
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1080,1)
001:Outro
002:11
003:305
004:10630
013:cm
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1081,1)
001:Descrição
002:4
003:1080
004:10640
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1082,1)
001:Acometimento de tonsilas palatinas?
002:11
003:552
004:2430

Location:^VARWorkFlowPEP(0,"C91.1",1083,1)
001:Lado Direito?
002:11
003:1082
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1084,1)
001:Tamanho
002:3
003:1083
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1085,1)
001:Lado Esquerdo?
002:11
003:1082
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1086,1)
001:Tamanho
002:3
003:1085
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1087,1)
001:Acometimento de tonsilas linguais?
002:11
003:552
004:10500

Location:^VARWorkFlowPEP(0,"C91.1",1088,1)
001:Lado Direito?
002:11
003:1087
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1089,1)
001:Tamanho
002:3
003:1088
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1090,1)
001:Lado Esquerdo?
002:11
003:1087
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1091,1)
001:Tamanho
002:3
003:1090
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1092,1)
001:Acometimento de tonsilas naosfaríngea?
002:11
003:552
004:10510

Location:^VARWorkFlowPEP(0,"C91.1",1093,1)
001:Lado Direito?
002:11
003:1092
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1094,1)
001:Tamanho
002:3
003:1093
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1095,1)
001:Lado Esquerdo?
002:11
003:1092
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1096,1)
001:Tamanho
002:3
003:1095
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1097,1)
001:Outro
002:11
003:552
004:10630
013:cm
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1098,1)
001:Descrição
002:4
003:1097
004:10640
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1116,1)
001:Acometimento de tonsilas palatinas?
002:11
003:756
004:2430

Location:^VARWorkFlowPEP(0,"C91.1",1117,1)
001:Lado Direito?
002:11
003:1116
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1118,1)
001:Tamanho
002:3
003:1117
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1119,1)
001:Lado Esquerdo?
002:11
003:1116
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1120,1)
001:Tamanho
002:3
003:1119
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1121,1)
001:Acometimento de tonsilas linguais?
002:11
003:756
004:10500

Location:^VARWorkFlowPEP(0,"C91.1",1122,1)
001:Lado Direito?
002:11
003:1121
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1123,1)
001:Tamanho
002:3
003:1122
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1124,1)
001:Lado Esquerdo?
002:11
003:1121
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1125,1)
001:Tamanho
002:3
003:1124
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1126,1)
001:Acometimento de tonsilas naosfaríngea?
002:11
003:756
004:10510

Location:^VARWorkFlowPEP(0,"C91.1",1127,1)
001:Lado Direito?
002:11
003:1126
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1128,1)
001:Tamanho
002:3
003:1127
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1129,1)
001:Lado Esquerdo?
002:11
003:1126
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1130,1)
001:Tamanho
002:3
003:1129
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1131,1)
001:Outro
002:11
003:756
004:10630
013:cm
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1132,1)
001:Descrição
002:4
003:1131
004:10640
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1133,1)
001:Acometimento de tonsilas palatinas?
002:11
003:858
004:2430

Location:^VARWorkFlowPEP(0,"C91.1",1134,1)
001:Lado Direito?
002:11
003:1133
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1135,1)
001:Tamanho
002:3
003:1134
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1136,1)
001:Lado Esquerdo?
002:11
003:1133
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1137,1)
001:Tamanho
002:3
003:1136
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1138,1)
001:Acometimento de tonsilas linguais?
002:11
003:858
004:10500

Location:^VARWorkFlowPEP(0,"C91.1",1139,1)
001:Lado Direito?
002:11
003:1138
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1140,1)
001:Tamanho
002:3
003:1139
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1141,1)
001:Lado Esquerdo?
002:11
003:1138
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1142,1)
001:Tamanho
002:3
003:1141
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1143,1)
001:Acometimento de tonsilas naosfaríngea?
002:11
003:858
004:10510

Location:^VARWorkFlowPEP(0,"C91.1",1144,1)
001:Lado Direito?
002:11
003:1143
004:10520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1145,1)
001:Tamanho
002:3
003:1144
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1146,1)
001:Lado Esquerdo?
002:11
003:1143
004:10550
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1147,1)
001:Tamanho
002:3
003:1146
004:10530
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1148,1)
001:Outro
002:11
003:858
004:10630
013:cm
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1149,1)
001:Descrição
002:4
003:1148
004:10640
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1150,1)
001:Quantas anormalidades cromossômicas?
002:3
003:115
004:11500
005:0
022:15

Location:^VARWorkFlowPEP(0,"C91.1",1152,1)
001:Quantas anormalidades cromossômicas?
002:3
003:122
004:11520
005:0
022:15

Location:^VARWorkFlowPEP(0,"C91.1",1154,1)
001:Outro Marcador?
002:14
003:444
004:4520
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1155,1)
001:Observações
002:4
003:10
004:11550
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1156,1)
001:Observações
002:4
003:37
004:11560
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1157,1)
001:Observações
002:4
003:38
004:11570
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1158,1)
001:Observações
002:4
003:39
004:11580
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1159,1)
001:Observações
002:4
003:5
004:11590
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1160,1)
001:Causa
002:4
003:455
004:11600
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1161,1)
001:119
002:5
003:7
004:1756
008:3
016:CMV

Location:^VARWorkFlowPEP(0,"C91.1",1162,1)
001:120
002:5
003:169
004:11620
005:0
008:1
019:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1163,1)
001:121
002:5
003:165
004:11630
005:0
008:1
019:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1164,1)
001:122
002:5
003:165
004:11640
005:0
008:1
019:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1165,1)
001:124
002:5
003:1161
004:11650
005:0
008:1
019:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1166,1)
001:123
002:5
003:168
004:11660
005:0
008:1
019:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1167,1)
001:1;23
002:7
003:1362
004:11670
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1168,1)
001:Mediastino anterior?
002:11
003:1568
004:11680
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1169,1)
001:Mediastino posterior?
002:11
003:1568
004:11690
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1170,1)
001:Número de linfonodos aumentados
002:3
003:1168
004:11700
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1171,1)
001:Tamanho do maior linfonodo
002:3
003:1168
004:11710
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1172,1)
001:Tem doença "Bulky"?
002:11
003:1168
004:11720
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1173,1)
001:Observações
002:4
003:1168
004:11730
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1174,1)
001:Número de linfonodos aumentados
002:3
003:1169
004:11740
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1175,1)
001:Tamanho do maior linfonodo
002:3
003:1169
004:11750
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1176,1)
001:Tem doença "Bulky"?
002:11
003:1169
004:11760
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1177,1)
001:Observações
002:4
003:1169
004:11770
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1178,1)
001:1;23
002:7
003:1363
004:11780
013:cm
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1179,1)
001:Mediastino anterior?
002:11
003:1651
004:11790
013:cm
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",1180,1)
001:Mediastino posterior?
002:11
003:1651
004:11800
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1181,1)
001:Número de linfonodos aumentados
002:3
003:1179
004:11810
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1182,1)
001:Tamanho do maior linfonodo
002:3
003:1179
004:11820
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1183,1)
001:Tem doença "Bulky"?
002:11
003:1179
004:11830
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1184,1)
001:Observações
002:4
003:1179
004:11840
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1185,1)
001:Número de linfonodos aumentados
002:3
003:1180
004:11850
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1186,1)
001:Tamanho do maior linfonodo
002:3
003:1180
004:11860
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1187,1)
001:Tem doença "Bulky"?
002:11
003:1180
004:11870
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1188,1)
001:Observações
002:4
003:1180
004:11880
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1189,1)
001:1;23
002:7
003:1365
004:11890
013:cm
022:0

Location:^VARWorkFlowPEP(0,"C91.1",1190,1)
001:Mediastino anterior?
002:11
003:1815
004:11900
013:cm
022:1
023: 

Location:^VARWorkFlowPEP(0,"C91.1",1191,1)
001:Mediastino posterior?
002:11
003:1815
004:11910
013:cm
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1192,1)
001:Número de linfonodos aumentados
002:3
003:1190
004:11920
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1193,1)
001:Tamanho do maior linfonodo
002:3
003:1190
004:11930
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1194,1)
001:Tem doença "Bulky"?
002:11
003:1190
004:11940
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1195,1)
001:Observações
002:4
003:1190
004:11950
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1196,1)
001:Número de linfonodos aumentados
002:3
003:1191
004:11960
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1197,1)
001:Tamanho do maior linfonodo
002:3
003:1191
004:11970
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1198,1)
001:Tem doença "Bulky"?
002:11
003:1191
004:11980
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1199,1)
001:Observações
002:4
003:1191
004:11990
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1201,1)
001:Linfonodomegalia progressiva sintomática\nou doença bulky (>10cm)?
002:2
003:1306
004:12010
016:Critérios de tratamento

Location:^VARWorkFlowPEP(0,"C91.1",1202,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1306
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1203,1)
001:Paciente tem complicações auto-imunes<br>não responsiva a corticóides ou outra terapia?
002:11
003:1306
004:12030

Location:^VARWorkFlowPEP(0,"C91.1",1204,1)
001:Paciente tem envolvimento extra-nodal sintomático?
002:11
003:1306
004:12040

Location:^VARWorkFlowPEP(0,"C91.1",1205,1)
001:Descrição
002:4
003:1204
004:12050
011:1000
012:4
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1206,1)
001:1;1
002:7
003:1201
004:710
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1207,1)
001:1;2
002:7
003:1201
004:720
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1208,1)
001:1;3
002:7
003:1201
004:730
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1209,1)
001:1;4
002:7
003:1201
004:740
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1210,1)
001:1;5
002:7
003:1201
004:750
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1211,1)
001:1;6
002:7
003:1201
004:760
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1212,1)
001:1;7
002:7
003:1201
004:770
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1213,1)
001:1;8
002:7
003:1201
004:780
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1214,1)
001:1;9
002:7
003:1201
004:790
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1215,1)
001:1;10
002:7
003:1201
004:800
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1216,1)
001:1;11
002:7
003:1201
004:810
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1217,1)
001:1;19
002:7
003:1201
004:1760
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1218,1)
001:1;20
002:7
003:1201
004:1770
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1219,1)
001:Outros
002:1
003:1201
004:8730
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1220,1)
001:Dor?
002:11
003:1206
004:122000

Location:^VARWorkFlowPEP(0,"C91.1",1221,1)
001:       Compressão?
002:11
003:1206
004:122100

Location:^VARWorkFlowPEP(0,"C91.1",1222,1)
001:Outros?
002:11
003:1206
004:122200

Location:^VARWorkFlowPEP(0,"C91.1",1223,1)
001:Descrição
002:4
003:1222
004:122200
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1224,1)
001:Dor?
002:11
003:1207
004:122400

Location:^VARWorkFlowPEP(0,"C91.1",1225,1)
001:       Compressão?
002:11
003:1207
004:122500

Location:^VARWorkFlowPEP(0,"C91.1",1226,1)
001:Outros?
002:11
003:1207
004:122600

Location:^VARWorkFlowPEP(0,"C91.1",1227,1)
001:Descrição
002:4
003:1226
004:122600
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1228,1)
001:Dor?
002:11
003:1208
004:122800

Location:^VARWorkFlowPEP(0,"C91.1",1229,1)
001:       Compressão?
002:11
003:1208
004:122900

Location:^VARWorkFlowPEP(0,"C91.1",1230,1)
001:Outros?
002:11
003:1208
004:123000

Location:^VARWorkFlowPEP(0,"C91.1",1231,1)
001:Descrição
002:4
003:1230
004:123000
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1232,1)
001:Dor?
002:11
003:1209
004:123200

Location:^VARWorkFlowPEP(0,"C91.1",1233,1)
001:       Compressão?
002:11
003:1209
004:123300

Location:^VARWorkFlowPEP(0,"C91.1",1234,1)
001:Outros?
002:11
003:1209
004:123400

Location:^VARWorkFlowPEP(0,"C91.1",1235,1)
001:Descrição
002:4
003:1234
004:123400
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1236,1)
001:Dor?
002:11
003:1210
004:123600

Location:^VARWorkFlowPEP(0,"C91.1",1237,1)
001:       Compressão?
002:11
003:1210
004:123700

Location:^VARWorkFlowPEP(0,"C91.1",1238,1)
001:Outros?
002:11
003:1210
004:123800

Location:^VARWorkFlowPEP(0,"C91.1",1239,1)
001:Descrição
002:4
003:1238
004:123800
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1240,1)
001:Dor?
002:11
003:1211
004:124000

Location:^VARWorkFlowPEP(0,"C91.1",1241,1)
001:       Compressão?
002:11
003:1211
004:124100

Location:^VARWorkFlowPEP(0,"C91.1",1242,1)
001:Outros?
002:11
003:1211
004:124200

Location:^VARWorkFlowPEP(0,"C91.1",1243,1)
001:Descrição
002:4
003:1242
004:124200
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1244,1)
001:Dor?
002:11
003:1212
004:124400

Location:^VARWorkFlowPEP(0,"C91.1",1245,1)
001:       Compressão?
002:11
003:1212
004:124500

Location:^VARWorkFlowPEP(0,"C91.1",1246,1)
001:Outros?
002:11
003:1212
004:124600

Location:^VARWorkFlowPEP(0,"C91.1",1247,1)
001:Descrição
002:4
003:1246
004:124600
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1248,1)
001:Dor?
002:11
003:1213
004:124800

Location:^VARWorkFlowPEP(0,"C91.1",1249,1)
001:       Compressão?
002:11
003:1213
004:124900

Location:^VARWorkFlowPEP(0,"C91.1",1250,1)
001:Outros?
002:11
003:1213
004:125000

Location:^VARWorkFlowPEP(0,"C91.1",1251,1)
001:Descrição
002:4
003:1250
004:125000
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1252,1)
001:Dor?
002:11
003:1214
004:125200

Location:^VARWorkFlowPEP(0,"C91.1",1253,1)
001:       Compressão?
002:11
003:1214
004:125300

Location:^VARWorkFlowPEP(0,"C91.1",1254,1)
001:Outros?
002:11
003:1214
004:125400

Location:^VARWorkFlowPEP(0,"C91.1",1255,1)
001:Descrição
002:4
003:1254
004:125400
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1256,1)
001:Dor?
002:11
003:1215
004:125600

Location:^VARWorkFlowPEP(0,"C91.1",1257,1)
001:       Compressão?
002:11
003:1215
004:125700

Location:^VARWorkFlowPEP(0,"C91.1",1258,1)
001:Outros?
002:11
003:1215
004:125800

Location:^VARWorkFlowPEP(0,"C91.1",1259,1)
001:Descrição
002:4
003:1258
004:125800
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1260,1)
001:Dor?
002:11
003:1216
004:126000

Location:^VARWorkFlowPEP(0,"C91.1",1261,1)
001:       Compressão?
002:11
003:1216
004:126100

Location:^VARWorkFlowPEP(0,"C91.1",1262,1)
001:Outros?
002:11
003:1216
004:126200

Location:^VARWorkFlowPEP(0,"C91.1",1263,1)
001:Descrição
002:4
003:1262
004:126200
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1264,1)
001:Dor?
002:11
003:1217
004:126400

Location:^VARWorkFlowPEP(0,"C91.1",1265,1)
001:       Compressão?
002:11
003:1217
004:126500

Location:^VARWorkFlowPEP(0,"C91.1",1266,1)
001:Outros?
002:11
003:1217
004:126600

Location:^VARWorkFlowPEP(0,"C91.1",1267,1)
001:Descrição
002:4
003:1266
004:126600
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1268,1)
001:Dor?
002:11
003:1218
004:126800

Location:^VARWorkFlowPEP(0,"C91.1",1269,1)
001:       Compressão?
002:11
003:1218
004:126900

Location:^VARWorkFlowPEP(0,"C91.1",1270,1)
001:Outros?
002:11
003:1218
004:127000

Location:^VARWorkFlowPEP(0,"C91.1",1271,1)
001:Descrição
002:4
003:1270
004:127000
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1275,1)
001:Descrição
002:4
003:1219
004:127400
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1277,1)
001:Paciente tem disfunções orgânicas?
002:2
003:1306
004:13190

Location:^VARWorkFlowPEP(0,"C91.1",1279,1)
001:Tamanho do Maior Linfonodo
002:3
003:83
004:12790
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1280,1)
001:Tem doença "Bulky"?
002:11
003:83
004:12800
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1281,1)
001:Observações
002:4
003:83
004:12810
011:1000
012:4
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1282,1)
001:Tamanho do Maior Linfonodo
002:3
003:84
004:12820
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1283,1)
001:Tem doença "Bulky"?
002:11
003:84
004:12830
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1284,1)
001:Observações
002:4
003:84
004:12840
011:1000
012:4
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1285,1)
001:Tamanho do Maior Linfonodo
002:3
003:85
004:12850
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1286,1)
001:Tem doença "Bulky"?
002:11
003:85
004:12860
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1287,1)
001:Observações
002:4
003:85
004:12870
011:1000
012:4
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1296,1)
001:Doença Hepática
002:11
003:1277
004:12960
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1297,1)
001:Doença renal
002:11
003:1277
004:12970
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1298,1)
001:Doença cardíaca
002:11
003:1277
004:12980
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1299,1)
001:Doença pulmonar
002:11
003:1277
004:12990
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1300,1)
001:Neuropatia
002:11
003:1277
004:13000
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1301,1)
001:Disfunção
002:4
003:1296
004:13010
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1302,1)
001:Disfunção
002:4
003:1297
004:13020
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1303,1)
001:Disfunção
002:4
003:1298
004:13030
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1304,1)
001:Disfunção
002:4
003:1299
004:13040
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1305,1)
001:Disfunção
002:4
003:1300
004:13050
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1306,1)
001:Conduta
002:15
004:13060
024:fas fa-notes-medical

Location:^VARWorkFlowPEP(0,"C91.1",1309,1)
001:Outro critério para tratamento?
002:11
003:1306
004:13170

Location:^VARWorkFlowPEP(0,"C91.1",1310,1)
001:Critério
002:4
003:1309
004:13100
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1311,1)
001:O paciente é frágil?
002:2
003:1306
004:13180

Location:^VARWorkFlowPEP(0,"C91.1",1312,1)
001:Escala de fragilidade
002:9
003:1311
004:13120
014:Muito bem - Robusto, ativo, com energia, realiza exercícios físicos regularmente, entre os melhores da sua idade|Bem - Sem sintomas, praticam exercícios físicos eventualmente, ativos|Autosuficiente - doença bem controlada, mas não muito ativos além de caminhadas rotineiras|Vulnerável - Independente porém os sintomas limitam as atividades. Uma queixa comum é a lentificação e cansaço|Levemente frágil - lentificação perceptível, precisam de ajuda com tarefas rotineiras (finanças, transporte, medicação e trabalhos domésticos)|Moderadamente frágil - Precisa de ajuda com todas as atividades externas, e para manter a casa. Tem problemas com escadas, e precisam de ajuda para o banho e eventualmente para se vestirem|Acentuadamente frágil - Totalmente dependente para auto-cuidado. No entanto são aparentemente estáveis, sem risco de morte iminente|Muito acentuadamente frágil - Totalmente dependente, próximos do final da vida. Tipicamente eles podem não se recuperar mesmo de doenças simples|Paciente terminal - Expectativa de vida menor que 6 meses, sem aparente fragilidade
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1314,1)
001:Sinais de falência medular progressiva<br>com anemia (Hb < 10 g / dl) ou<br>trombocitopenia (plaquetas < 100.000 / ml)?
002:11
003:1306
004:13140

Location:^VARWorkFlowPEP(0,"C91.1",1315,1)
001:Esplenomegalia massiva (> 6cm abaixo<br>do rebordo costal esquerdo) ou sintomática?
002:11
003:1306
004:13150

Location:^VARWorkFlowPEP(0,"C91.1",1316,1)
001:Algum sintoma relacionado à doença?
002:9
003:1306
004:13160
014:Perda de mais de 10% do peso corporal nos últimos 6 meses|Fadiga significativa (ECOG 2 ou mais)|Febre (38º C por pelo menos 2 semanas sem evidência de infecção)|Sudorese noturna por pelo menos 1 mês sem evidência de infecção
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1319,1)
001:Conduta terapêutica
002:19
004:13190

Location:^VARWorkFlowPEP(0,"C91.1",1320,1)
001:Avaliação de Resposta
002:19
004:13200

Location:^VARWorkFlowPEP(0,"C91.1",1321,1)
001:Toxicidade
002:19
004:13210

Location:^VARWorkFlowPEP(0,"C91.1",1322,1)
001:Avaliação de Resposta
002:9
003:1320
004:13220
014:Remissão completa|Remissão completa com doença residual mínima negativa|Remissão completa com doença residual mínima positiva|Remissão completa com recuperação medular incompleta|Remissão Parcial (resposta incompleta)|Doença estável|Progressão de doença

Location:^VARWorkFlowPEP(0,"C91.1",1328,1)
001:Toxicidade hematológica
002:9
003:1321
004:13280
014:Neutropenia|Plaquetopenia|Anemia
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1329,1)
001:Síndrome de lise tumoral
002:11
003:1321
004:13290

Location:^VARWorkFlowPEP(0,"C91.1",1330,1)
001:Infecções
002:9
003:1321
004:13300
014:Bacteriana|Viral|Fúngica|Infecção não caracterizada
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1331,1)
001:Cardíaca
002:9
003:1321
004:13310
014:Arritmia|Doença coronariana|Outra toxicidade cardíaca
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1332,1)
001:Gastrointestinal
002:9
003:1321
004:13320
014:Diarréia|Colite auto-imune|Outra toxicidade gastrointestinal
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1333,1)
001:Sangramentos
002:11
003:1321
004:13330

Location:^VARWorkFlowPEP(0,"C91.1",1334,1)
001:Pulmonar
002:9
003:1321
004:13340
014:Pneumonite auto-imune|Outra toxicidade gastrointestinal
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1335,1)
001:Renal
002:9
003:1321
004:13350
014:Aumento de creatinina|Aumento de ureia|Proteinúria
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1336,1)
001:Hepática
002:9
003:1321
004:13360
014:Aumento de bilirrubinas|Aumento de transaminases|Aumento de fosfatase alcalina e gama GT|Insuficiência hepática
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1337,1)
001:Outra toxicidade
002:11
003:1321
004:13370

Location:^VARWorkFlowPEP(0,"C91.1",1338,1)
001:Infecção
002:4
003:1330
004:13380
011:1000
012:2
022:4

Location:^VARWorkFlowPEP(0,"C91.1",1339,1)
001:Toxicidade
002:4
003:1331
004:13390
011:1000
012:2
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1340,1)
001:Toxicidade
002:4
003:1332
004:13400
011:1000
012:2
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1341,1)
001:Creatinina
002:3
003:1335
004:13410
005:0
007:1
013:mg/dl
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1342,1)
001:Bilirrubina direta
002:3
003:1336
004:13420
005:0
007:1
013:mg/dl
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1343,1)
001:Toxicidade
002:4
003:1334
004:13430
011:1000
012:2
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1344,1)
001:Toxicidade
002:4
003:1337
004:13440
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1345,1)
001:Linfócitos em sangue periférico < 4.000 / ul<br>Ausência de linfonodomegalias com mais de 1,5 cm<br>Ausência de hepatomegalia<br>Ausência de esplenomegalia<br>Ausência de sintomas B<br>Neutrófilos > 1500 / ul<br>Plaquetas > 100.000 / ul<br>Hemoglobina > 11 g/dl (sem transfusão ou fator de crescimento)
002:20
003:1322
004:13450
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1346,1)
001:Linfócitos em sangue periférico < 4.000 / ul<br>Ausência de linfonodomegalias com mais de 1,5 cm<br>Ausência de hepatomegalia (fígado aumentado) e esplenomegalia (baço aumentado)<br>Ausência de sintomas B<br>Neutrófilos < 1500 / ul e/ ou Plaquetas < 100.000 / ul e / ou Hemoglobina < 11 g/dl (sem transfusão ou fator de crescimento)
002:20
003:1322
004:13460
022:4

Location:^VARWorkFlowPEP(0,"C91.1",1347,1)
001:Informe as caracteristicas para progressão de doença
002:9
003:1322
004:13470
014:Aumento >50% em qualquer linfonodo anterior|Aparecimento de novas lesões (esplenomegalia, hepatomegalia, linfonodos ou outros orgãos. Aumento transitório de linfonodos associado ao tratamento com inibidores de BTK não devem ser considerados como novas lesões)|Aumento do número de linfócitos (>50% - Linfocitose transitória transitório associada a tratamento com inibidores de BTK não devem ser considerados como progressão)|Transformação para histologia mais agressiva (Richter)|Surgimento de citopenia associada a LLC, não relacionada a fenômenos auto-imunes (fora de terapia)
015:1
022:7

Location:^VARWorkFlowPEP(0,"C91.1",1348,1)
001:Informe as caracteristicas para remissão parcial
002:9
003:1322
004:13480
014:O paciente apresentou redução entre 50% e 99% da linfonodomegalia|O paciente apresentou redução entre 50% e 99% da linfocitose|O paciente apresentou redução entre 50% e 99% da hepatomegalia|O paciente apresentou redução entre 50% e 99% da esplenomegalia|O paciente apresenta sintomas B|Plaquetas > 100.000 / ul ou Aumento de 50% na contagem de plaquetas|Hemoglobina > 11 g/dl ou aumento de 50% no nível de hemoglobina (sem transfusão ou fator de crescimento)|Há doença medular detectável
015:1
022:5

Location:^VARWorkFlowPEP(0,"C91.1",1349,1)
001:Continuidade do Tratamento
002:21
003:1319
004:13490

Location:^VARWorkFlowPEP(0,"C91.1",1350,1)
001:Paciente tem Hepatomegalia ao Exame Físico?
002:11
003:1517
004:2

Location:^VARWorkFlowPEP(0,"C91.1",1351,1)
001:Paciente tem Esplenomegalia ao Exame Físico?
002:11
003:1517
004:3

Location:^VARWorkFlowPEP(0,"C91.1",1352,1)
001:Realizou Análise Citogenética?
002:11
003:112
004:13520
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1353,1)
001:Realizou Análise Citogenética?
002:11
003:111
004:13530
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1354,1)
001:Ureia
002:3
003:1335
004:13540
005:0
007:1
013:mg/dl
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1355,1)
001:Proteinúria
002:3
003:1335
004:13550
005:0
007:1
013:mg/24h
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1356,1)
001:Bilirrubina indireta
002:3
003:1336
004:13560
005:0
007:1
013:mg/dl
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1357,1)
001:AST
002:3
003:1336
004:13570
005:0
007:1
013:mg/dl
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1358,1)
001:ALT
002:3
003:1336
004:13580
005:0
007:1
013:mg/dl
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1359,1)
001:Fosfatase Alcalina
002:3
003:1336
004:13590
005:0
007:1
013:mg/dl
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1360,1)
001:Gama GT
002:3
003:1336
004:13600
005:0
007:1
013:mg/dl
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1361,1)
001:Neurológica
002:9
003:1321
004:13360
013:mg/dl
014:Neuropatia periférica|Encefalopatia|AVC
015:1

Location:^VARWorkFlowPEP(0,"C91.1",1362,1)
001:O Exame foi normal?
002:11
003:456
004:13620
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1363,1)
001:O Exame foi normal?
002:11
003:457
004:13630
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1364,1)
001:O Exame foi normal?
002:11
003:458
004:13640
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1365,1)
001:O Exame foi normal?
002:11
003:459
004:13650
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1366,1)
001:O Exame foi normal?
002:11
003:460
004:13660
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1367,1)
001:Monoclonalidade
002:9
003:1369
004:4439
014:Monoclonalidade (restrição) de cadeia leve Kappa|Monoclonalidade (restrição) de cadeia leve Lambda|Não foi detectada monoclonalidade de cadeia leve
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1368,1)
001:Monoclonalidade
002:9
003:188
004:8709
014:Monoclonalidade (restrição) de cadeia leve Kappa|Monoclonalidade (restrição) de cadeia leve Lambda|Não foi detectada monoclonalidade de cadeia leve
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1369,1)
001:Realizou imunofenotipagem de sangue periférico?
002:11
003:10
004:1000
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1370,1)
001:Submandibular Esquerdo?
002:11
003:76
004:13700
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1371,1)
001:Submandibular Direito?
002:11
003:76
004:13710
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1372,1)
001:Número de linfonodos aumentados
002:3
003:1371
004:13720
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1373,1)
001:Tamanho do maior linfonodo
002:3
003:1371
004:13730
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1374,1)
001:Tem doença "Bulky"?
002:11
003:1371
004:13740
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1375,1)
001:Observações
002:4
003:1371
004:13750
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1376,1)
001:Submandibular Direito?
002:11
003:1686
004:13760
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1377,1)
001:Número de linfonodos aumentados
002:3
003:1376
004:13770
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1378,1)
001:Tamanho do maior linfonodo
002:3
003:1376
004:13780
005:0
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1379,1)
001:Tem doença "Bulky"?
002:11
003:1376
004:13790
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1380,1)
001:Observações
002:4
003:1376
004:13800
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1381,1)
001:Submandibular Direito?
002:11
003:1685
004:13810
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1382,1)
001:Número de linfonodos aumentados
002:3
003:1381
004:13820
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1383,1)
001:Tamanho do maior linfonodo
002:3
003:1381
004:13830
005:0
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1384,1)
001:Tem doença "Bulky"?
002:11
003:1381
004:13840
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1385,1)
001:Observações
002:4
003:1381
004:13850
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1386,1)
001:Submandibular Direito?
002:11
003:1882
004:13860
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1387,1)
001:Número de linfonodos aumentados
002:3
003:1386
004:13870
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1388,1)
001:Tamanho do maior linfonodo
002:3
003:1386
004:13880
005:0
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1389,1)
001:Tem doença "Bulky"?
002:11
003:1386
004:13890
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1390,1)
001:Maior captação
002:3
003:1386
004:13900
005:0
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1391,1)
001:Observações
002:4
003:1386
004:13910
011:1000
012:2
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1392,1)
001:Submandibular Direito?
002:11
003:1883
004:13920
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1393,1)
001:Número de linfonodos aumentados
002:3
003:1392
004:13930
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1394,1)
001:Tamanho do maior linfonodo
002:3
003:1392
004:13940
005:0
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1395,1)
001:Tem doença "Bulky"?
002:11
003:1392
004:13950
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1396,1)
001:Observações
002:4
003:1392
004:13960
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1398,1)
001:Modificar o tratamento do paciente?
002:2
003:1349
004:13980
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1401,1)
001:Data dos Exames
002:13
003:1369
004:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1402,1)
001:Data de Realização dos Exames
002:13
003:101
004:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1403,1)
001:Data de Realização dos Exames
002:13
003:102
004:10
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1404,1)
001:Submentoniano?
002:11
003:76
004:14040

Location:^VARWorkFlowPEP(0,"C91.1",1405,1)
001:Número de linfonodos aumentados
002:3
003:1404
004:14050
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1406,1)
001:Tamanho do maior linfonodo
002:3
003:1404
004:14060
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1407,1)
001:Tem doença "Bulky"?
002:11
003:1404
004:14070
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1408,1)
001:Observações
002:4
003:1404
004:14080
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1409,1)
001:Submentoniano?
002:11
003:1686
004:14090
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1410,1)
001:Submentoniano?
002:11
003:1685
004:14100
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1411,1)
001:Submentoniano?
002:11
003:1882
004:14110
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1412,1)
001:Submentoniano?
002:11
003:1883
004:14120
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1413,1)
001:Número de linfonodos aumentados
002:3
003:1409
004:14130
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1414,1)
001:Tamanho do maior linfonodo
002:3
003:1409
004:14140
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1415,1)
001:Tem doença "Bulky"?
002:11
003:1409
004:14150
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1416,1)
001:Observações
002:4
003:1409
004:14160
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1417,1)
001:Número de linfonodos aumentados
002:3
003:1410
004:14170
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1418,1)
001:Tamanho do maior linfonodo
002:3
003:1410
004:14180
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1419,1)
001:Tem doença "Bulky"?
002:11
003:1410
004:14190
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1420,1)
001:Observações
002:4
003:1410
004:14200
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1421,1)
001:Número de linfonodos aumentados
002:3
003:1411
004:14210
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1422,1)
001:Tamanho do maior linfonodo
002:3
003:1411
004:14220
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1423,1)
001:Tem doença "Bulky"?
002:11
003:1411
004:14230
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1424,1)
001:Observações
002:4
003:1411
004:14240
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1425,1)
001:Número de linfonodos aumentados
002:3
003:1412
004:14250
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1426,1)
001:Tamanho do maior linfonodo
002:3
003:1412
004:14260
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1427,1)
001:Tem doença "Bulky"?
002:11
003:1412
004:14270
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1428,1)
001:Observações
002:4
003:1412
004:14280
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1429,1)
001:Axilar Esquerda
002:11
003:327
004:14290
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1430,1)
001:Axilar Direita
002:11
003:327
004:14300
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1431,1)
001:Axilar Esquerda
002:11
003:487
004:14310
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1432,1)
001:Axilar Direita
002:11
003:487
004:14320
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1433,1)
001:Axilar Esquerda
002:11
003:691
004:14330
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1434,1)
001:Axilar Direita
002:11
003:691
004:14340
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1435,1)
001:Axilar Esquerda
002:11
003:793
004:14350
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1436,1)
001:Axilar Direita
002:11
003:793
004:14360
022:1
023:0

Location:^VARWorkFlowPEP(0,"C91.1",1437,1)
001:Número de linfonodos aumentados
002:3
003:1430
004:14370
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1438,1)
001:Tamanho do maior linfonodo
002:3
003:1430
004:14380
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1439,1)
001:Tem doença "Bulky"?
002:11
003:1430
004:14390
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1440,1)
001:Observações
002:4
003:1430
004:14400
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1441,1)
001:Número de linfonodos aumentados
002:3
003:1432
004:14410
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1442,1)
001:Tamanho do maior linfonodo
002:3
003:1432
004:14420
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1443,1)
001:Tem doença "Bulky"?
002:11
003:1432
004:14430
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1444,1)
001:Observações
002:4
003:1432
004:14440
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1445,1)
001:Número de linfonodos aumentados
002:3
003:1434
004:14450
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1446,1)
001:Tamanho do maior linfonodo
002:3
003:1434
004:14460
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1447,1)
001:Tem doença "Bulky"?
002:11
003:1434
004:14470
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1448,1)
001:Maior captação
002:3
003:1434
004:14480
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1449,1)
001:Observações
002:4
003:1434
004:14490
011:1000
012:2
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1450,1)
001:Número de linfonodos aumentados
002:3
003:1436
004:14500
005:0
007:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1451,1)
001:Tamanho do maior linfonodo
002:3
003:1436
004:14510
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1452,1)
001:Tem doença "Bulky"?
002:11
003:1436
004:14520
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1453,1)
001:Observações
002:4
003:1436
004:14530
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1454,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:72
004:14540
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1455,1)
001:1;24
002:7
003:69
004:14550
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1456,1)
001:Paciente Tem Linfonodomegalia na Região Diafragmática?
002:11
003:1455
004:14560
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1457,1)
001:Número de linfonodos aumentados
002:3
003:1456
004:14570
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1458,1)
001:Tamanho do maior linfonodo
002:3
003:1456
004:14580
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1459,1)
001:Tem doença "Bulky"?
002:11
003:1456
004:14590
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1460,1)
001:Observações
002:4
003:1456
004:14600
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1461,1)
001:Volume do baço
002:3
003:337
004:14610
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1462,1)
001:Volume do baço
002:3
003:499
004:14620
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1463,1)
001:Volume do baço
002:3
003:703
004:14630
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1464,1)
001:Volume do baço
002:3
003:805
004:14640
005:0
007:1
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1465,1)
001:Inserir Exames Adicionais
002:22
003:7
004:1960
016:Exames Adicionais

Location:^VARWorkFlowPEP(0,"C91.1",1468,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1720
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1469,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1721
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1470,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1722
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1471,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1723
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1472,1)
001:Paciente tem linfocitose progressiva,<br>com tempo de duplicação menor que 6 meses?
002:11
003:1724
004:12020

Location:^VARWorkFlowPEP(0,"C91.1",1473,1)
001:Nome do Exame
002:4
003:1479
004:14730
011:3000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1479,1)
001:Outros Exames de Imagem
002:10
003:3
004:14790

Location:^VARWorkFlowPEP(0,"C91.1",1480,1)
001:Resultado
002:4
003:1479
004:14800
011:3000
012:10

Location:^VARWorkFlowPEP(0,"C91.1",1481,1)
001:Doença residual mínima
002:10
003:1
004:14810

Location:^VARWorkFlowPEP(0,"C91.1",1482,1)
001:Realizou pesquisa de doença residual mínima?
002:11
003:1481
004:14820
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1486,1)
001:Doença residual em DRM por imunofenotipagem
002:9
003:1482
004:14860
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1487,1)
001:Doença residual em DRM por biologia molecular (PCR)
002:9
003:1482
004:14870
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1488,1)
001:Doença residual em DRM por sequenciamento<br>de DNA de nova geração (NGS)
002:9
003:1482
004:14880
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1489,1)
001:Percentual Detectável
002:3
003:1486
004:14890
005:0
006:100
007:1
013:%
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1490,1)
001:Observações
002:4
003:1487
004:14900
011:1000
012:3
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1491,1)
001:Observações
002:4
003:1488
004:14910
011:1000
012:3
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1492,1)
001:Doença residual mínima
002:10
003:2
004:14920

Location:^VARWorkFlowPEP(0,"C91.1",1493,1)
001:Realizou pesquisa de doença residual mínima?
002:11
003:1492
004:14930
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1497,1)
001:Doença residual em DRM por imunofenotipagem
002:9
003:1493
004:14970
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1498,1)
001:Doença residual em DRM por biologia molecular (PCR)
002:9
003:1493
004:14980
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1499,1)
001:Doença residual em DRM por sequenciamento<br>de DNA de nova geração (NGS)
002:9
003:1493
004:14990
014:Doença residual mínima indetectável|Doença residual mínima detectável
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1500,1)
001:Percentual Detectável
002:3
003:1497
004:15000
005:0
006:100
007:1
013:%
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1501,1)
001:Observações
002:4
003:1498
004:15010
011:1000
012:3
013:%
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1502,1)
001:Observações
002:4
003:1499
004:15020
011:1000
012:3
013:%
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1503,1)
001:Informe as caracteristicas para doença estável
002:9
003:1322
004:15030
014:O paciente apresentou diminuição < 50% da linfocitose|O paciente apresentou aumento < 50% da linfocitose|O paciente apresentou diminuição < 50% da linfonodomegalia|O paciente apresentou aumento < 50% da linfonodomegalia|O paciente apresentou aumento < 50% da esplenomegalia|O paciente apresentou diminuição < 50% da esplenomegalia|O paciente apresentou aumento < 50% da hepatomegalia|O paciente apresentou diminuição < 50% da hepatomegalia|O paciente apresenta sintomas B|O paciente apresentou aumento < 50% da contagem de plaquetas|O paciente apresentou diminuição < 50% da contagem de plaquetas|O paciente apresentou Hemoglobina < 11 g/dL ou aumento < 50% do nível basal de hemoglobina|O paciente apresentou diminuição <2 g/dL da Hemoglobina|Infiltrado de medula inalterado
022:6

Location:^VARWorkFlowPEP(0,"C91.1",1504,1)
001:Imunofenotipagem
002:9
003:1322
004:15040
014:DRM não detectada|DRM detectada
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1505,1)
001:Imunofenotipagem
002:9
003:1322
004:15050
014:DRM não detectada|DRM detectada
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1506,1)
001:Biologia molecular (detecção de rearranjo VDJ)
002:9
003:1322
004:15060
014:DRM não detectada|DRM detectada
022:3

Location:^VARWorkFlowPEP(0,"C91.1",1507,1)
001:Biologia molecular (detecção de rearranjo VDJ)
002:9
003:1322
004:15070
014:DRM não detectada|DRM detectada
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1508,1)
001:Descrição
002:4
003:1504
004:15080
011:1000
012:2
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1509,1)
001:Descrição
002:4
003:1507
004:15090
011:1000
012:2
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1510,1)
001:Descrição
002:4
003:1505
004:15100
011:1000
012:2
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1511,1)
001:Descrição
002:4
003:1506
004:15110
011:1000
012:2
022:2

Location:^VARWorkFlowPEP(0,"C91.1",1512,1)
001:Progressão da Doença
002:11
003:1398
004:15120
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1513,1)
001:Toxidade
002:11
003:1398
004:15130
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1514,1)
001:Outros
002:11
003:1398
004:15140
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1516,1)
001:Motivo
002:4
003:1514
004:15160
011:1000
012:4
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1517,1)
001:Exame Físico Direcionado
002:10
003:4
004:4

Location:^VARWorkFlowPEP(0,"C91.1",1518,1)
001:Sintomas B
002:10
003:4
004:5

Location:^VARWorkFlowPEP(0,"C91.1",1519,1)
001:Conduta e observações
002:4
003:1306
004:13195
011:1000
012:2

Location:^VARWorkFlowPEP(0,"C91.1",1520,1)
001:Pré Auricular Esquerdo?
002:11
003:312
004:15200
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1521,1)
001:Retro Auricular Esquerdo?
002:11
003:312
004:15210
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1522,1)
001:Pré Auricular Direito?
002:11
003:312
004:15220
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1523,1)
001:Retro Auricular Direito?
002:11
003:312
004:15230
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1524,1)
001:Número de linfonodos aumentados
002:3
003:1521
004:15240
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1525,1)
001:Tamanho do maior linfonodo
002:3
003:1521
004:15250
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1526,1)
001:Tem doença "Bulky"?
002:11
003:1521
004:15260
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1527,1)
001:Observações
002:4
003:1521
004:15270
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1528,1)
001:Número de linfonodos aumentados
002:3
003:1522
004:15280
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1529,1)
001:Tamanho do maior linfonodo
002:3
003:1522
004:15290
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1530,1)
001:Tem doença "Bulky"?
002:11
003:1522
004:15300
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1531,1)
001:Observações
002:4
003:1522
004:15310
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1532,1)
001:Número de linfonodos aumentados
002:3
003:1523
004:15320
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1533,1)
001:Tamanho do maior linfonodo
002:3
003:1523
004:15330
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1534,1)
001:Tem doença "Bulky"?
002:11
003:1523
004:15340
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1535,1)
001:Observações
002:4
003:1523
004:15350
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1536,1)
001:Cervical Anterior Esquerdo?
002:11
003:377
004:15360
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1537,1)
001:Cervical Anterior Direito?
002:11
003:377
004:15370
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1538,1)
001:Cervical Posterior Esquerdo?
002:11
003:377
004:15380
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1539,1)
001:Cervical Posterior Direito?
002:11
003:377
004:15390
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1540,1)
001:Número de Linfonodos Aumentados
002:3
003:1537
004:15400
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1541,1)
001:Tamanho do Maior Linfonodo
002:3
003:1537
004:15410
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1542,1)
001:Tem doença "Bulky"?
002:11
003:1537
004:15420
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1543,1)
001:Observações
002:4
003:1537
004:15430
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1544,1)
001:Número de Linfonodos Aumentados
002:3
003:1538
004:15440
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1545,1)
001:Tamanho do Maior Linfonodo
002:3
003:1538
004:15450
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1546,1)
001:Tem doença "Bulky"?
002:11
003:1538
004:15460
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1547,1)
001:Observações
002:4
003:1538
004:15470
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1548,1)
001:Número de Linfonodos Aumentados
002:3
003:1539
004:15480
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1549,1)
001:Tamanho do Maior Linfonodo
002:3
003:1539
004:15490
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1550,1)
001:Tem doença "Bulky"?
002:11
003:1539
004:15500
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1551,1)
001:Observações
002:4
003:1539
004:15510
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1552,1)
001:Ilíaco Esquerdo
002:11
003:357
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1553,1)
001:Número de linfonodos aumentados
002:3
003:1552
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1554,1)
001:Tamanho do maior linfonodo
002:3
003:1552
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1555,1)
001:Tem doença "Bulky"?
002:11
003:1552
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1556,1)
001:Observações
002:4
003:1552
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1557,1)
001:Ilíaco Direito?
002:11
003:357
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1558,1)
001:Número de linfonodos aumentados
002:3
003:1557
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1559,1)
001:Tamanho do maior linfonodo
002:3
003:1557
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1560,1)
001:Tem doença "Bulky"?
002:11
003:1557
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1561,1)
001:Observações
002:4
003:1557
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1562,1)
001:Inguinal Direito
002:11
003:1567
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1563,1)
001:Número de linfonodos aumentados
002:3
003:1562
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1564,1)
001:Tamanho do maior linfonodo
002:3
003:1562
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1565,1)
001:Tem doença "Bulky"?
002:11
003:1562
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1566,1)
001:Observações
002:4
003:1562
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1567,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:298
004:15670
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1568,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:1167
004:15680
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1569,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:306
004:15690
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1570,1)
001:Mesentérico Direito?
002:11
003:1569
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1571,1)
001:Número de linfonodos aumentados
002:3
003:1570
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1572,1)
001:Tamanho do maior linfonodo
002:3
003:1570
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1573,1)
001:Tem doença "Bulky"?
002:11
003:1570
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1574,1)
001:Observações
002:4
003:1570
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1575,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:301
004:15750
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1576,1)
001:Para-aórtico Direito?
002:11
003:1575
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1577,1)
001:Número de linfonodos aumentados
002:3
003:1576
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1578,1)
001:Tamanho do maior linfonodo
002:3
003:1576
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1579,1)
001:Tem doença "Bulky"?
002:11
003:1576
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1580,1)
001:Observações
002:4
003:1576
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1581,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:293
004:15810
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1582,1)
001:Peitoral Direito?
002:11
003:1581
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1583,1)
001:Número de linfonodos aumentados
002:3
003:1582
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1584,1)
001:Tamanho do maior linfonodo
002:3
003:1582
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1585,1)
001:Tem doença "Bulky"?
002:11
003:1582
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1586,1)
001:Observações
002:4
003:1582
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1587,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:468
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1588,1)
001:Pré Auricular Esquerdo?
002:11
003:1587
004:15200
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1589,1)
001:Número de linfonodos aumentados
002:3
003:1588
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1590,1)
001:Tamanho do maior linfonodo
002:3
003:1588
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1591,1)
001:Tem doença "Bulky"?
002:11
003:1588
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1592,1)
001:Observações
002:4
003:1588
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1593,1)
001:Retro Auricular Esquerdo?
002:11
003:1587
004:15210
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1594,1)
001:Número de linfonodos aumentados
002:3
003:1593
004:15240
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1595,1)
001:Tamanho do maior linfonodo
002:3
003:1593
004:15250
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1596,1)
001:Tem doença "Bulky"?
002:11
003:1593
004:15260
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1597,1)
001:Observações
002:4
003:1593
004:15270
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1598,1)
001:Pré Auricular Direito?
002:11
003:1587
004:15220
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1599,1)
001:Número de linfonodos aumentados
002:3
003:1598
004:15280
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1600,1)
001:Tamanho do maior linfonodo
002:3
003:1598
004:15290
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1601,1)
001:Tem doença "Bulky"?
002:11
003:1598
004:15300
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1602,1)
001:Observações
002:4
003:1598
004:15310
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1603,1)
001:Retro Auricular Direito?
002:11
003:1587
004:15230
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1604,1)
001:Número de linfonodos aumentados
002:3
003:1603
004:15320
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1605,1)
001:Tamanho do maior linfonodo
002:3
003:1603
004:15330
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1606,1)
001:Tem doença "Bulky"?
002:11
003:1603
004:15340
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1607,1)
001:Observações
002:4
003:1603
004:15350
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1608,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:546
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1609,1)
001:Cervical Anterior Esquerdo?
002:11
003:1608
004:15360
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1610,1)
001:Número de linfonodos aumentados
002:3
003:1609
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1611,1)
001:Tamanho do maior linfonodo
002:3
003:1609
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1612,1)
001:Tem doença "Bulky"?
002:11
003:1609
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1613,1)
001:Observações
002:4
003:1609
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1614,1)
001:Cervical Anterior Direito?
002:11
003:1608
004:15370
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1615,1)
001:Número de Linfonodos Aumentados
002:3
003:1614
004:15400
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1616,1)
001:Tamanho do Maior Linfonodo
002:3
003:1614
004:15410
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1617,1)
001:Tem doença "Bulky"?
002:11
003:1614
004:15420
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1618,1)
001:Observações
002:4
003:1614
004:15430
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1619,1)
001:Cervical Posterior Esquerdo?
002:11
003:1608
004:15380
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1620,1)
001:Número de Linfonodos Aumentados
002:3
003:1619
004:15440
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1621,1)
001:Tamanho do Maior Linfonodo
002:3
003:1619
004:15450
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1622,1)
001:Tem doença "Bulky"?
002:11
003:1619
004:15460
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1623,1)
001:Observações
002:4
003:1619
004:15470
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1624,1)
001:Cervical Posterior Direito?
002:11
003:1608
004:15390
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1625,1)
001:Número de Linfonodos Aumentados
002:3
003:1624
004:15480
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1626,1)
001:Tamanho do Maior Linfonodo
002:3
003:1624
004:15490
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1627,1)
001:Tem doença "Bulky"?
002:11
003:1624
004:15500
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1628,1)
001:Observações
002:4
003:1624
004:15510
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1629,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:522
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1630,1)
001:Ilíaco Esquerdo
002:11
003:1629
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1631,1)
001:Número de linfonodos aumentados
002:3
003:1630
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1632,1)
001:Tamanho do maior linfonodo
002:3
003:1630
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1633,1)
001:Tem doença "Bulky"?
002:11
003:1630
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1634,1)
001:Observações
002:4
003:1630
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1635,1)
001:Ilíaco Direito?
002:11
003:1629
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1636,1)
001:Número de linfonodos aumentados
002:3
003:1635
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1637,1)
001:Tamanho do maior linfonodo
002:3
003:1635
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1638,1)
001:Tem doença "Bulky"?
002:11
003:1635
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1639,1)
001:Observações
002:4
003:1635
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1640,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:510
004:15670
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1641,1)
001:Inguinal Esquerdo
002:11
003:1640
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1642,1)
001:Número de linfonodos aumentados
002:3
003:1641
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1643,1)
001:Tamanho do maior linfonodo
002:3
003:1641
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1644,1)
001:Tem doença "Bulky"?
002:11
003:1641
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1645,1)
001:Observações
002:4
003:1641
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1646,1)
001:Inguinal Direito
002:11
003:1640
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1647,1)
001:Número de linfonodos aumentados
002:3
003:1646
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1648,1)
001:Tamanho do maior linfonodo
002:3
003:1646
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1649,1)
001:Tem doença "Bulky"?
002:11
003:1646
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1650,1)
001:Observações
002:4
003:1646
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1651,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:1178
004:16510
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1652,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:558
004:15690
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1653,1)
001:Mesentérico Esquerdo
002:11
003:1652
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1654,1)
001:Número de linfonodos aumentados
002:3
003:1653
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1655,1)
001:Tamanho do maior linfonodo
002:3
003:1653
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1656,1)
001:Tem doença "Bulky"?
002:11
003:1653
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1657,1)
001:Observações
002:4
003:1653
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1658,1)
001:Mesentérico Direito?
002:11
003:1652
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1659,1)
001:Número de linfonodos aumentados
002:3
003:1658
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1660,1)
001:Tamanho do maior linfonodo
002:3
003:1658
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1661,1)
001:Tem doença "Bulky"?
002:11
003:1658
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1662,1)
001:Observações
002:4
003:1658
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1663,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:528
004:15750
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1664,1)
001:Para-aórtico Esquerdo?
002:11
003:1663
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1665,1)
001:Número de linfonodos aumentados
002:3
003:1664
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1666,1)
001:Tamanho do maior linfonodo
002:3
003:1664
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1667,1)
001:Tem doença "Bulky"?
002:11
003:1664
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1668,1)
001:Observações
002:4
003:1664
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1669,1)
001:Para-aórtico Direito?
002:11
003:1663
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1670,1)
001:Número de linfonodos aumentados
002:3
003:1669
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1671,1)
001:Tamanho do maior linfonodo
002:3
003:1669
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1672,1)
001:Tem doença "Bulky"?
002:11
003:1669
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1673,1)
001:Observações
002:4
003:1669
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1674,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:480
004:15810
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1675,1)
001:Peitoral Esquerdo
002:11
003:1674
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1676,1)
001:Número de linfonodos aumentados
002:3
003:1675
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1677,1)
001:Tamanho do maior linfonodo
002:3
003:1675
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1678,1)
001:Tem doença "Bulky"?
002:11
003:1675
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1679,1)
001:Observações
002:4
003:1675
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1680,1)
001:Peitoral Direito?
002:11
003:1674
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1681,1)
001:Número de linfonodos aumentados
002:3
003:1680
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1682,1)
001:Tamanho do maior linfonodo
002:3
003:1680
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1683,1)
001:Tem doença "Bulky"?
002:11
003:1680
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1684,1)
001:Observações
002:4
003:1680
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1685,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:474
004:16850
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1686,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:292
004:16860
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1687,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:672
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1688,1)
001:Pré Auricular Esquerdo?
002:11
003:1687
004:15200
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1689,1)
001:Número de linfonodos aumentados
002:3
003:1688
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1690,1)
001:Tamanho do maior linfonodo
002:3
003:1688
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1691,1)
001:Tem doença "Bulky"?
002:11
003:1688
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1692,1)
001:Observações
002:4
003:1688
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1693,1)
001:Retro Auricular Esquerdo?
002:11
003:1687
004:15210
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1694,1)
001:Número de linfonodos aumentados
002:3
003:1693
004:15240
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1695,1)
001:Tamanho do maior linfonodo
002:3
003:1693
004:15250
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1696,1)
001:Tem doença "Bulky"?
002:11
003:1693
004:15260
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1697,1)
001:Observações
002:4
003:1693
004:15270
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1698,1)
001:Pré Auricular Direito?
002:11
003:1687
004:15220
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1699,1)
001:Número de linfonodos aumentados
002:3
003:1698
004:15280
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1700,1)
001:Tamanho do maior linfonodo
002:3
003:1698
004:15290
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1701,1)
001:Tem doença "Bulky"?
002:11
003:1698
004:15300
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1702,1)
001:Observações
002:4
003:1698
004:15310
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1703,1)
001:Retro Auricular Direito?
002:11
003:1687
004:15230
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1704,1)
001:Número de linfonodos aumentados
002:3
003:1703
004:15320
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1705,1)
001:Tamanho do maior linfonodo
002:3
003:1703
004:15330
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1706,1)
001:Tem doença "Bulky"?
002:11
003:1703
004:15340
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1707,1)
001:Observações
002:4
003:1703
004:15350
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1708,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:774
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1709,1)
001:Pré Auricular Esquerdo?
002:11
003:1708
004:15200
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1710,1)
001:Número de linfonodos aumentados
002:3
003:1709
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1711,1)
001:Tamanho do maior linfonodo
002:3
003:1709
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1712,1)
001:Tem doença "Bulky"?
002:11
003:1709
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1713,1)
001:Observações
002:4
003:1709
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1714,1)
001:Retro Auricular Esquerdo?
002:11
003:1708
004:15210
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1715,1)
001:Número de linfonodos aumentados
002:3
003:1714
004:15240
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1716,1)
001:Tamanho do maior linfonodo
002:3
003:1714
004:15250
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1717,1)
001:Tem doença "Bulky"?
002:11
003:1714
004:15260
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1718,1)
001:Observações
002:4
003:1714
004:15270
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1719,1)
001:Pré Auricular Direito?
002:11
003:1708
004:15220
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1720,1)
001:Número de linfonodos aumentados
002:3
003:1719
004:15280
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1721,1)
001:Tamanho do maior linfonodo
002:3
003:1719
004:15290
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1722,1)
001:Tem doença "Bulky"?
002:11
003:1719
004:15300
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1723,1)
001:Observações
002:4
003:1719
004:15310
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1724,1)
001:Retro Auricular Direito?
002:11
003:1708
004:15230
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1725,1)
001:Número de linfonodos aumentados
002:3
003:1724
004:15320
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1726,1)
001:Tamanho do maior linfonodo
002:3
003:1724
004:15330
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1727,1)
001:Tem doença "Bulky"?
002:11
003:1724
004:15340
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1728,1)
001:Observações
002:4
003:1724
004:15350
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1729,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:750
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1730,1)
001:Cervical Anterior Esquerdo?
002:11
003:1729
004:15360
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1731,1)
001:Número de linfonodos aumentados
002:3
003:1730
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1732,1)
001:Tamanho do maior linfonodo
002:3
003:1730
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1733,1)
001:Tem doença "Bulky"?
002:11
003:1730
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1734,1)
001:Observações
002:4
003:1730
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1735,1)
001:Cervical Anterior Direito?
002:11
003:1729
004:15370
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1736,1)
001:Número de Linfonodos Aumentados
002:3
003:1735
004:15400
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1737,1)
001:Tamanho do Maior Linfonodo
002:3
003:1735
004:15410
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1738,1)
001:Tem doença "Bulky"?
002:11
003:1735
004:15420
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1739,1)
001:Observações
002:4
003:1735
004:15430
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1740,1)
001:Cervical Posterior Esquerdo?
002:11
003:1729
004:15380
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1741,1)
001:Número de Linfonodos Aumentados
002:3
003:1740
004:15440
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1742,1)
001:Tamanho do Maior Linfonodo
002:3
003:1740
004:15450
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1743,1)
001:Tem doença "Bulky"?
002:11
003:1740
004:15460
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1744,1)
001:Observações
002:4
003:1740
004:15470
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1745,1)
001:Cervical Posterior Direito?
002:11
003:1729
004:15390
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1746,1)
001:Número de Linfonodos Aumentados
002:3
003:1745
004:15480
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1747,1)
001:Tamanho do Maior Linfonodo
002:3
003:1745
004:15490
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1748,1)
001:Tem doença "Bulky"?
002:11
003:1745
004:15500
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1749,1)
001:Observações
002:4
003:1745
004:15510
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1750,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:852
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1751,1)
001:Cervical Anterior Esquerdo?
002:11
003:1750
004:15360
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1752,1)
001:Número de linfonodos aumentados
002:3
003:1751
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1753,1)
001:Tamanho do maior linfonodo
002:3
003:1751
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1754,1)
001:Tem doença "Bulky"?
002:11
003:1751
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1755,1)
001:Observações
002:4
003:1751
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1756,1)
001:Cervical Anterior Direito?
002:11
003:1750
004:15370
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1757,1)
001:Número de Linfonodos Aumentados
002:3
003:1756
004:15400
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1758,1)
001:Tamanho do Maior Linfonodo
002:3
003:1756
004:15410
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1759,1)
001:Tem doença "Bulky"?
002:11
003:1756
004:15420
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1760,1)
001:Observações
002:4
003:1756
004:15430
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1761,1)
001:Cervical Posterior Esquerdo?
002:11
003:1750
004:15380
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1762,1)
001:Número de Linfonodos Aumentados
002:3
003:1761
004:15440
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1763,1)
001:Tamanho do Maior Linfonodo
002:3
003:1761
004:15450
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1764,1)
001:Tem doença "Bulky"?
002:11
003:1761
004:15460
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1765,1)
001:Observações
002:4
003:1761
004:15470
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1766,1)
001:Cervical Posterior Direito?
002:11
003:1750
004:15390
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1767,1)
001:Número de Linfonodos Aumentados
002:3
003:1766
004:15480
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1768,1)
001:Tamanho do Maior Linfonodo
002:3
003:1766
004:15490
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1769,1)
001:Tem doença "Bulky"?
002:11
003:1766
004:15500
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1770,1)
001:Observações
002:4
003:1766
004:15510
011:1000
012:2
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1771,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:726
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1772,1)
001:Ilíaco Esquerdo
002:11
003:1771
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1773,1)
001:Número de linfonodos aumentados
002:3
003:1772
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1774,1)
001:Tamanho do maior linfonodo
002:3
003:1772
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1775,1)
001:Tem doença "Bulky"?
002:11
003:1772
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1776,1)
001:Observações
002:4
003:1772
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1777,1)
001:Ilíaco Direito?
002:11
003:1771
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1778,1)
001:Número de linfonodos aumentados
002:3
003:1777
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1779,1)
001:Tamanho do maior linfonodo
002:3
003:1777
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1780,1)
001:Tem doença "Bulky"?
002:11
003:1777
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1781,1)
001:Observações
002:4
003:1777
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1782,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:828
004:2430
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1783,1)
001:Ilíaco Esquerdo
002:11
003:1782
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1784,1)
001:Número de linfonodos aumentados
002:3
003:1783
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1785,1)
001:Tamanho do maior linfonodo
002:3
003:1783
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1786,1)
001:Tem doença "Bulky"?
002:11
003:1783
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1787,1)
001:Observações
002:4
003:1783
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1788,1)
001:Ilíaco Direito?
002:11
003:1782
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1789,1)
001:Número de linfonodos aumentados
002:3
003:1788
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1790,1)
001:Tamanho do maior linfonodo
002:3
003:1788
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1791,1)
001:Tem doença "Bulky"?
002:11
003:1788
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1792,1)
001:Observações
002:4
003:1788
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1793,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:714
004:15670
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1794,1)
001:Inguinal Esquerdo
002:11
003:1793
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1795,1)
001:Número de linfonodos aumentados
002:3
003:1794
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1796,1)
001:Tamanho do maior linfonodo
002:3
003:1794
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1797,1)
001:Tem doença "Bulky"?
002:11
003:1794
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1798,1)
001:Observações
002:4
003:1794
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1799,1)
001:Inguinal Direito
002:11
003:1793
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1800,1)
001:Número de linfonodos aumentados
002:3
003:1799
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1801,1)
001:Tamanho do maior linfonodo
002:3
003:1799
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1802,1)
001:Tem doença "Bulky"?
002:11
003:1799
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1803,1)
001:Observações
002:4
003:1799
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1804,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:816
004:15670
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1805,1)
001:Inguinal Esquerdo
002:11
003:1804
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1806,1)
001:Número de linfonodos aumentados
002:3
003:1805
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1807,1)
001:Tamanho do maior linfonodo
002:3
003:1805
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1808,1)
001:Tem doença "Bulky"?
002:11
003:1805
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1809,1)
001:Observações
002:4
003:1805
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1810,1)
001:Inguinal Direito
002:11
003:1804
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1811,1)
001:Número de linfonodos aumentados
002:3
003:1810
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1812,1)
001:Tamanho do maior linfonodo
002:3
003:1810
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1813,1)
001:Tem doença "Bulky"?
002:11
003:1810
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1814,1)
001:Observações
002:4
003:1810
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1815,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:1189
004:18150
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1816,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:762
004:15690
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1817,1)
001:Mesentérico Esquerdo
002:11
003:1816
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1818,1)
001:Número de linfonodos aumentados
002:3
003:1817
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1819,1)
001:Tamanho do maior linfonodo
002:3
003:1817
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1820,1)
001:Tem doença "Bulky"?
002:11
003:1817
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1821,1)
001:Observações
002:4
003:1817
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1822,1)
001:Mesentérico Direito?
002:11
003:1816
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1823,1)
001:Número de linfonodos aumentados
002:3
003:1822
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1824,1)
001:Tamanho do maior linfonodo
002:3
003:1822
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1825,1)
001:Tem doença "Bulky"?
002:11
003:1822
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1826,1)
001:Observações
002:4
003:1822
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1827,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:864
004:15690
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1828,1)
001:Mesentérico Esquerdo
002:11
003:1827
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1829,1)
001:Número de linfonodos aumentados
002:3
003:1828
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1830,1)
001:Tamanho do maior linfonodo
002:3
003:1828
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1831,1)
001:Tem doença "Bulky"?
002:11
003:1828
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1832,1)
001:Observações
002:4
003:1828
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1833,1)
001:Mesentérico Direito?
002:11
003:1827
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1834,1)
001:Número de linfonodos aumentados
002:3
003:1833
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1835,1)
001:Tamanho do maior linfonodo
002:3
003:1833
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1836,1)
001:Tem doença "Bulky"?
002:11
003:1833
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1837,1)
001:Observações
002:4
003:1833
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1838,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:732
004:15750
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1839,1)
001:Para-aórtico Esquerdo?
002:11
003:1838
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1840,1)
001:Número de linfonodos aumentados
002:3
003:1839
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1841,1)
001:Tamanho do maior linfonodo
002:3
003:1839
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1842,1)
001:Tem doença "Bulky"?
002:11
003:1839
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1843,1)
001:Observações
002:4
003:1839
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1844,1)
001:Para-aórtico Direito?
002:11
003:1838
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1845,1)
001:Número de linfonodos aumentados
002:3
003:1844
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1846,1)
001:Tamanho do maior linfonodo
002:3
003:1844
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1847,1)
001:Tem doença "Bulky"?
002:11
003:1844
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1848,1)
001:Observações
002:4
003:1844
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1849,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:834
004:15750
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1850,1)
001:Para-aórtico Esquerdo?
002:11
003:1849
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1851,1)
001:Número de linfonodos aumentados
002:3
003:1850
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1852,1)
001:Tamanho do maior linfonodo
002:3
003:1850
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1853,1)
001:Tem doença "Bulky"?
002:11
003:1850
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1854,1)
001:Observações
002:4
003:1850
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1855,1)
001:Para-aórtico Direito?
002:11
003:1849
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1856,1)
001:Número de linfonodos aumentados
002:3
003:1855
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1857,1)
001:Tamanho do maior linfonodo
002:3
003:1855
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1858,1)
001:Tem doença "Bulky"?
002:11
003:1855
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1859,1)
001:Observações
002:4
003:1855
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1860,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:684
004:15810
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1861,1)
001:Peitoral Esquerdo
002:11
003:1860
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1862,1)
001:Número de linfonodos aumentados
002:3
003:1861
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1863,1)
001:Tamanho do maior linfonodo
002:3
003:1861
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1864,1)
001:Tem doença "Bulky"?
002:11
003:1861
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1865,1)
001:Observações
002:4
003:1861
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1866,1)
001:Peitoral Direito?
002:11
003:1860
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1867,1)
001:Número de linfonodos aumentados
002:3
003:1866
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1868,1)
001:Tamanho do maior linfonodo
002:3
003:1866
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1869,1)
001:Tem doença "Bulky"?
002:11
003:1866
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1870,1)
001:Observações
002:4
003:1866
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1871,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:786
004:15810
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1872,1)
001:Peitoral Esquerdo
002:11
003:1871
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1873,1)
001:Número de linfonodos aumentados
002:3
003:1872
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1874,1)
001:Tamanho do maior linfonodo
002:3
003:1872
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1875,1)
001:Tem doença "Bulky"?
002:11
003:1872
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1876,1)
001:Observações
002:4
003:1872
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1877,1)
001:Peitoral Direito?
002:11
003:1871
004:2430
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1878,1)
001:Número de linfonodos aumentados
002:3
003:1877
004:2250
005:0
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1879,1)
001:Tamanho do maior linfonodo
002:3
003:1877
004:2270
005:0
007:1
013:cm
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1880,1)
001:Tem doença "Bulky"?
002:11
003:1877
004:2290
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1881,1)
001:Observações
002:4
003:1877
004:2410
011:1000
012:2
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1882,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:678
004:18820
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1883,1)
001:Paciente Tem Linfonodomegalia?
002:11
003:780
004:18830
023:1

Location:^VARWorkFlowPEP(0,"C91.1",1884,1)
001:Maior captação
002:3
003:1688
004:2409
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1885,1)
001:Maior captação
002:3
003:1693
004:15265
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1886,1)
001:Maior captação
002:3
003:1411
004:18860
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1887,1)
001:Maior captação
002:3
003:1698
004:15305
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1888,1)
001:Maior captação
002:3
003:1703
004:15345
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1889,1)
001:Maior captação
002:3
003:1730
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1890,1)
001:Maior captação
002:3
003:1735
004:15425
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1891,1)
001:Maior captação
002:3
003:1740
004:15465
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1892,1)
001:Maior captação
002:3
003:1745
004:15505
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1893,1)
001:Maior captação
002:3
003:1772
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1894,1)
001:Maior captação
002:3
003:1777
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1895,1)
001:Maior captação
002:3
003:1794
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1896,1)
001:Maior captação
002:3
003:1799
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1897,1)
001:Maior captação
002:3
003:1190
004:11940
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1898,1)
001:Maior captação
002:3
003:1191
004:11985
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1899,1)
001:Maior captação
002:3
003:1817
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1900,1)
001:Maior captação
002:3
003:1822
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1901,1)
001:Maior captação
002:3
003:1839
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1902,1)
001:Maior captação
002:3
003:1844
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1903,1)
001:Maior captação
002:3
003:1861
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1904,1)
001:Maior captação
002:3
003:1866
004:2405
005:0
007:1
013:SUV
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1906,1)
001:Regime Terapeutico
002:16
003:1306
004:19060

Location:^VARWorkFlowPEP(0,"C91.1",1907,1)
001:Anamnese
002:4
003:461
004:19070
011:2000
012:4

Location:^VARWorkFlowPEP(0,"C91.1",1908,1)
001:Exame Físico
002:4
003:461
004:19080
011:2000
012:4

Location:^VARWorkFlowPEP(0,"C91.1",1909,1)
001:Tabagismo?
002:11
003:461
004:19090
016:Antecedentes Pessoais

Location:^VARWorkFlowPEP(0,"C91.1",1910,1)
001:Etilismo?
002:11
003:461
004:19100
016:Antecedentes Pessoais

Location:^VARWorkFlowPEP(0,"C91.1",1911,1)
001:Quantos maços ao dia?
002:3
003:1909
004:19110
005:1
006:999
013:maços
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1912,1)
001:Observações
002:4
003:1910
004:19120
011:2000
012:2
013: 
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1913,1)
001:Doença
002:29
003:461
004:19130
013: 
016:Doenças Anteriores e Atuais

Location:^VARWorkFlowPEP(0,"C91.1",1914,1)
001:Cirurgias anteriores?
002:4
003:461
004:19140
011:2000
012:2
013: 
016:Antecedentes Pessoais

Location:^VARWorkFlowPEP(0,"C91.1",1915,1)
001:Diag. anterior ou<br>atual de câncer?
002:11
003:461
004:19150
013: 
016:Antecedentes Pessoais

Location:^VARWorkFlowPEP(0,"C91.1",1916,1)
001:Em qual orgão?
002:4
003:1915
004:19160
011:2000
012:2
013: 
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1917,1)
001:Diag. ant. ou atual de<br>doenças hematológicas?
002:11
003:461
004:19170
013: 
016:Antecedentes Pessoais

Location:^VARWorkFlowPEP(0,"C91.1",1918,1)
001:Doença hematológica
002:4
003:1917
004:19180
011:2000
012:2
013: 
022:1

Location:^VARWorkFlowPEP(0,"C91.1",1919,1)
001:Medicamentos
002:30
003:461
004:19190
013: 
016:Medicamentos em uso

Location:^VARWorkFlowPEP(0,"C91.1",1920,1)
001:Doença ant.<br>e atual
002:31
003:461
004:19200
013: 
016:Antecedentes Familiares (Pai, mãe e irmãos)

Location:^VARWorkFlowPEP(0,"C91.1",1921,1)
001:Alergias
002:4
003:461
004:19082
011:2000
012:2
013: 

Location:^VARWorkFlowPEP(0,"C91.1",1922,1)
001:Observações
002:4
003:461
004:19192
011:1000
012:2
016:Medicamentos em uso

Location:^VARWorkFlowPEP(0,"C91.1",1923,1)
001:Tratamento
002:6
003:1398
004:19230
022:0

Node:^VARWorkFlowCID(0,"C91.1")
; Workflow de Atendimento - CID

Location:^VARWorkFlowCID(0,"C91.1",1)
001:LLC

Node:^VARWorkFlowEstPont(0,"C91.1")
; Estadiamento - Pontuação

Location:^VARWorkFlowEstPont(0,"C91.1",3,1,1)
001:4 pontos
002:4

Location:^VARWorkFlowEstPont(0,"C91.1",3,2,1)
001:2 pontos
002:2

Location:^VARWorkFlowEstPont(0,"C91.1",3,3,1)
001:2 pontos
002:2

Location:^VARWorkFlowEstPont(0,"C91.1",3,4,1)
001:1 ponto
002:1

Location:^VARWorkFlowEstPont(0,"C91.1",3,5,1)
001:1 ponto
002:1

Location:^VARWorkFlowEstPont(0,"C91.1",3,6,1)
001:Informativos
002:0

Node:^VARWorkFlowEstPontCondicao(0,"C91.1")
; Estadiamento - Condições da Pontuação

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,1,1,1,1)
001:142;1
002:>
003:0
004:0
005:Presença de mutação em TP53

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,1,2,1,1)
001:122;3|115;3
002:>
003:0
004:0
005:Alteração citogenética detectada Del 17p

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,2,1,1,1)
001:141;2
002:=
003:1
005:IGVH não mutado

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,3,3,1,1)
001:155
002:>
003:3.5

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,4,1,1,1)
001:1;5|1;4|1;3|1;2
002:>
003:0
004:1

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,5,1,1,1)
001:1
002:>
003:64
004:2
005:Paciente com mais de 65 anos

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,6,1,1,1)
001:1
002:<
003:65
004:2
005:Paciente com menos de 65 anos

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,6,2,1,1)
001:142;2
002:=
003:1
004:0
005:Ausência de mutação em TP53

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,6,3,1,1)
001:115;3|122;3
002:=
003:0
004:0
005:Ausência de alteração citogenética em Del 17p

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,6,4,1,1)
001:141;1
002:=
003:1
005:IGVH mutado

Location:^VARWorkFlowEstPontCondicao(0,"C91.1",3,6,5,1,1)
001:155
002:<
003:3.6
004:0

Node:^VARWorkFlowEstadiamento(0,"C91.1")
; WorkFLow - Estadiamento

Location:^VARWorkFlowEstadiamento(0,"C91.1",1,1)
001:RAI

Location:^VARWorkFlowEstadiamento(0,"C91.1",2,1)
001:BINET

Location:^VARWorkFlowEstadiamento(0,"C91.1",3,1)
001:CLL-IPI

Node:^VARWorkFlowEstadiamentoEstagio(0,"C91.1")
; Estágios do Estadiamento

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,1,1)
001:Estágio 0
002:Risco Baixo

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,2,1)
001:Estágio I
002:Risco Intermediário

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,3,1)
001:Estágio II
002:Risco Intermediário

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,4,1)
001:Estágio III
002:Risco Alto

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,5,1)
001:Estágio IV
002:Risco Alto

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",1,6,1)
001:Estágio Impossível
002:Estágio Não Calculável

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",2,1,1)
001:Estágio A
002:Risco Baixo

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",2,2,1)
001:Estágio B
002:Risco Intermediário

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",2,3,1)
001:Estágio C
002:Risco Alto

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",2,4,1)
001:Estágio Impossível
002:Estágio Não Calculável

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",3,1,1)
001:Estágio I
002:Risco Baixo

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",3,2,1)
001:Estágio II
002:Risco Intermediário

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",3,3,1)
001:Estágio III
002:Risco Alto

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",3,4,1)
001:Estágio IV
002:Risco Muito Alto

Location:^VARWorkFlowEstadiamentoEstagio(0,"C91.1",3,5,1)
001:Estágio Impossível
002:Estágio Não Calculável

Node:^VARWorkFlowEstEstagioC(0,"C91.1")
; Cadastro de Condições para o Estágio de Estadiamento

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,3,1)
001:243|244|245|255|260|265|270|275|285
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,4,1)
001:1350
002:=
003:0
004:Ausência de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,1,6,1)
001:455|102|101
002:=
003:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,4,1)
001:1350
002:=
003:0
004:Ausência de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,1,2,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,4,1)
001:1350
002:=
003:0
004:Ausência de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,1,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,4,1)
001:1350
002:=
003:0
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,5,1)
001:1351
002:=
003:0
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,2,2,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,5,1)
001:1351
002:=
003:1
004:Presença de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,1,7,1)
001:69
002:=
003:1
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,5,1)
001:1351
002:=
003:1
004:Presença de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,2,7,1)
001:69
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,4,1)
001:1350
002:=
003:1
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,7,1)
001:69
002:=
003:1
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,3,8,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,4,1)
001:1350
002:=
003:1
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,3,4,7,1)
001:69
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,2,1)
001:32
002:<>
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,1,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,2,1)
001:32
002:<>
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,4,2,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,1,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,3,1)
001:285|859|1050|1051|1063|199|200|201|202|82|83|84|85|875|876|1370|1371|1404|881|882|233|234|887|888|223|224|893|894|874|1456
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,2,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,3,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,5,4,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,1,1,1)
001:455
002:>
004:O paciente tem outra causa para anemia hemolítica auto-imune ou trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,1,2,1)
001:101|102
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,2,1,1)
001:455|101
002:=
003:2
004:O paciente tem anemia hemolítica auto-imune e outra causa para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,2,2,1)
001:102
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,3,1,1)
001:455|102
002:=
003:2
004:O paciente tem trombocitopenia auto-imune e outra causa para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,3,2,1)
001:101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,4,1,1)
001:455|101|102
002:=
003:3
004:O paciente tem anemia hemolítica auto-imune, trombocitopenia auto-imune e outra causa<br>para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,5,1,1)
001:101
002:=
003:1
004:O paciente tem anemia hemolítica auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,5,2,1)
001:102|455
002:=
003:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,6,1,1)
001:102
002:=
003:1
004:O paciente tem trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,6,2,1)
001:101|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,7,1,1)
001:102|101
002:=
003:2
004:O paciente tem anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento RAI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",1,6,7,2,1)
001:455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,4,1)
001:1350
002:=
003:0
004:Ausência de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,5,1)
001:1351
002:=
003:0
004:Ausência de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,1,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,3,1)
001:285|253|1052|1055|1056|1057|1058|199|200|201|202|82|83|84|85|875|876|1370|1371|881|882|233|234|887|888|223|224|893|894
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,2,7,1)
001:1454|243|244|245|1350|1351
002:<
003:3
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,3,1)
001:285|253|1052|1055|1056|1057|1058|199|200|201|202|82|83|84|85|875|876|1370|1371|881|882|233|234|887|888|223|224|893|894
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,7,1)
001:1351|1350
002:<
003:3
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,1,3,8,1)
001:69
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,3,1)
001:1404|894|893|224|223|888|887|234|233|882|881|1371|1370|876|875|85|84|83|82|202|201|200|199|1058|1057|1056|1055|1052|253|285
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,2,1,8,1)
001:1454|243|244|245|1350|1351
002:>
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,3,1)
001:1404|894|893|224|223|888|887|234|233|882|881|1371|1370|876|875|85|84|83|82|202|201|200|199|1058|1057|1056|1055|1052|253|285
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,1,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,3,1)
001:1404|894|893|224|223|888|887|234|233|882|881|1371|1370|876|875|85|84|83|82|202|201|200|199|1058|1057|1056|1055|1052|253|285
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,2,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,3,1)
001:1404|894|893|224|223|888|887|234|233|882|881|1371|1370|876|875|85|84|83|82|202|201|200|199|1058|1057|1056|1055|1052|253|285
002:<>
004:Presença de <cont> áreas com linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,3,7,1)
001:69
002:=
003:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,2,1)
001:32
002:>
003:100000
004:Ausência de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,4,6,1)
001:101|102|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,1,1)
001:13
002:>
003:11
004:Ausência de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,5,1)
001:1351
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,5,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,1,1)
001:13
002:<
003:11.1
004:Presença de anemia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,2,1)
001:32
002:<
003:100000.1
004:Presença de trombocitopenia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,3,1)
001:69
002:=
003:0
004:Ausência de linfonodomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,4,1)
001:1350
002:<>
004:<presenca> de hepatomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,5,1)
001:69
002:<>
004:<presenca> de esplenomegalia
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,3,6,6,1)
001:455|102|101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,1,1,1)
001:455
002:>
004:O paciente tem outra causa para anemia hemolítica auto-imune ou trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,1,2,1)
001:101|102
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,2,1,1)
001:455|101
002:=
003:2
004:O paciente tem anemia hemolítica auto-imune e outra causa para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,2,2,1)
001:102
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,3,1,1)
001:455|102
002:=
003:2
004:O paciente tem trombocitopenia auto-imune e outra causa para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,3,2,1)
001:101
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,4,1,1)
001:102|101|455
002:=
003:3
004:O paciente tem anemia hemolítica auto-imune, trombocitopenia auto-imune e outra causa<br>para anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,5,1,1)
001:101
002:=
003:1
004:O paciente tem anemia hemolítica auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,5,2,1)
001:102|455
002:=
003:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,6,1,1)
001:102
002:=
003:1
004:O paciente tem trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,6,2,1)
001:101|455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,7,1,1)
001:102|101
002:=
003:2
004:O paciente tem anemia hemolítica auto-imune e trombocitopenia auto-imune, portanto o estadiamento BINET não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",2,4,7,2,1)
001:455
002:=
003:0
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,1,1,1,1)
001:6|1|2|4|3|5
002:<
003:2
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,1,1,2,1)
001:142
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,1,2,1,1)
001:6|1|2|4|3|5
002:<
003:2
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,1,2,2,1)
001:414
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,2,1,1,1)
001:6|5|4|3|2|1
002:>
003:1
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,2,1,2,1)
001:142
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,2,2,1,1)
001:6|5|4|3|2|1
002:>
003:1
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,2,2,2,1)
001:414
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,3,1,1,1)
001:6|5|4|3|2|1
002:>
003:3
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,3,1,2,1)
001:142
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,3,2,1,1)
001:6|5|4|3|2|1
002:>
003:3
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,3,2,2,1)
001:414
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,4,1,1,1)
001:6|1|2|3|4|5
002:>
003:6
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,4,1,2,1)
001:142
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,4,2,1,1)
001:6|1|2|3|4|5
002:>
003:6
005:1

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,4,2,2,1)
001:414
002:<
003:2
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,5,1,1,1)
001:142
002:=
003:2
004:O paciente não realizou a análise de biologia molecular em TP53, portanto o estadiamento CLL-IPI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,5,2,1,1)
001:414
002:=
003:2
004:O paciente não realizou a análise de biologia molecular em TP53, portanto o estadiamento CLL-IPI não pode ser calculado
005:0

Location:^VARWorkFlowEstEstagioC(0,"C91.1",3,5,3,1,1)
001:196
002:=
003:0
004:O paciente não realizou a análise de biologia molecular em TP53, portanto o estadiamento CLL-IPI não pode ser calculado
005:0

Node:^VARWorkFlowTerapia(0,"C91.1")
; Cadastro de Sugestões Terapêuticas do PEP Premium

Location:^VARWorkFlowTerapia(0,"C91.1",1,1,1)
001:Pacientes sem critério para tratamento

Location:^VARWorkFlowTerapia(0,"C91.1",1,2,1)
001:Pacientes sem mutação em TP53 ou del 17p- E sem doenças cardiacas (Paciente com mais de 65 anos ou Paciente frágil ou paciente com menos de 65 anos com co-morbidades (clearence de creatinina < 70 ml/24h))

Location:^VARWorkFlowTerapia(0,"C91.1",1,3,1)
001:Pacientes sem mutação em TP53 ou del 17p- E sem doenças cardiacas (Paciente com menos de 65 anos sem co-morbidades)

Location:^VARWorkFlowTerapia(0,"C91.1",1,4,1)
001:Pacientes com mutação em TP53 ou del 17p- E sem doenças cardiaca

Location:^VARWorkFlowTerapia(0,"C91.1",1,5,1)
001:Pacientes sem mutação em TP53 ou del 17p- E com doenças cardiacas (Paciente com mais de 65 anos ou Paciente frágil ou paciente com menos de 65 anos com co-morbidades (clearence de creatinina < 70 ml/24h))

Location:^VARWorkFlowTerapia(0,"C91.1",1,6,1)
001:Pacientes sem mutação em TP53 ou del 17p- E com doenças cardiacas (Paciente com menos de 65 anos sem co-morbidades)

Location:^VARWorkFlowTerapia(0,"C91.1",1,7,1)
001:Pacientes com mutação em TP53 ou del 17p- E com doenças cardiaca

Node:^VARWorkFlowTerapiaCondicoes(0,"C91.1")
; Núcleo de Regras das Sugestões Terapêuticas do PEP Premium

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,1,1,1,1)
002:196
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,1,2,1,1)
001:Paciente sem mutação em TP53
002:142
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,2,1,1,1)
001:Paciente sem mutação em Del 17p-
002:122;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,3,1,1,1)
001:Paciente sem mutação em Del 17p-
002:115;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,4,1,1,1)
001:Paciente com mais de 65 anos
002:1
003:>
004:64
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,4,2,2,1)
001:Paciente frágil
002:1311
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,4,3,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,4,3,3,1)
001:Paciente com co-morbidades
002:1277
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,5,1,1,1)
001:Paciente sem doença cardiaca
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,2,5,2,1,1)
001:Paciente sem doença cardiaca
002:1298
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,1,1,1,1)
002:196
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,1,2,1,1)
001:Paciente sem mutação em TP53
002:142
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,2,1,1,1)
001:Paciente sem mutação em Del 17p-
002:122;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,3,1,1,1)
001:Paciente sem mutação em Del 17p-
002:115;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,4,1,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,4,1,3,1)
001:Paciente sem co-morbidades
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,5,1,1,1)
001:Paciente sem doença cardiaca
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,3,5,2,1,1)
001:Paciente sem doença cardiaca
002:1298
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,1,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,2,1,1)
001:Paciente com mais de 65 anos
002:1
003:>
004:64
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,3,1,1)
001:Paciente frágil
002:1311
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,4,1,1)
001:Paciente com co-morbidades
002:1277
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,5,1,1)
001:Paciente sem co-morbidades
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,6,1,1)
001:Paciente com mutação em TP53
002:142
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,8,1,1)
001:Paciente com mutação em Del 17p-
002:122;3
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,1,10,1,1)
001:Paciente com mutação em Del 17p-
002:115;3
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,2,1,1,1)
001:Paciente sem doença cardiaca
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,4,2,2,1,1)
001:Paciente sem doença cardiaca
002:1298
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,1,1,1,1)
002:196
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,1,2,1,1)
001:Paciente sem mutação em TP53
002:142
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,2,1,1,1)
001:Paciente sem mutação em Del 17p-
002:122;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,3,1,1,1)
001:Paciente sem mutação em Del 17p-
002:115;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,4,1,1,1)
001:Paciente com mais de 65 anos
002:1
003:>
004:64
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,4,2,2,1)
001:Paciente frágil
002:1311
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,4,3,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,4,3,3,1)
001:Paciente com co-morbidades
002:1277
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,5,5,1,1,1)
001:Paciente com doença cardiaca
002:1298
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,1,1,1,1)
002:196
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,1,2,1,1)
001:Paciente sem mutação em TP53
002:142
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,2,1,1,1)
001:Paciente sem mutação em Del 17p-
002:122;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,3,1,1,1)
001:Paciente sem mutação em Del 17p-
002:115;3
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,4,1,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,4,1,3,1)
001:Paciente sem co-morbidades
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,6,5,1,1,1)
001:Paciente com doença cardiaca
002:1298
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,1,1,1)
001:Paciente com menos de 65 anos
002:1
003:<
004:65
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,2,1,1)
001:Paciente com mais de 65 anos
002:1
003:>
004:64
005:2

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,3,1,1)
001:Paciente frágil
002:1311
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,4,1,1)
001:Paciente com co-morbidades
002:1277
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,5,1,1)
001:Paciente sem co-morbidades
002:1277
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,6,1,1)
001:Paciente com mutação em TP53
002:142
003:=
004:0
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,8,1,1)
001:Paciente com mutação em Del 17p-
002:122;3
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,1,10,1,1)
001:Paciente com mutação em Del 17p-
002:115;3
003:=
004:1
005:0

Location:^VARWorkFlowTerapiaCondicoes(0,"C91.1",1,7,2,1,1,1)
001:Paciente com doença cardiaca
002:1298
003:=
004:1
005:0

Node:^VARWorkFlowTerapiaMedicacao(0,"C91.1")
; Sugestões Terapêuticas do PEP Premium

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,1,1)
001:Acalabrutinibe
002:1
003:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,2,1)
001:Venetoclax
002:4

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,7,1)
001:Ibrutinibe (categoria 1)
002:2
003:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,8,1)
001:Ibrutinibe + Obinutuzumabe (categoria 2B)
002:8

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,11,1)
001:Clorambucil + Obinutuzumabe
002:15

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,14,1)
001:Metilprednisolona em altas doses + Rituximabe (categoria 2B)
002:18

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,15,1)
001:Obinutuzumabe (categoria 2B)
002:22

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,21,1)
001:Bendamustina (70mg/m2 no ciclo 1 com escalonamento para 90mg/m2 se bem tolerado) + anticorpo monoclonal anti-CD20 (não recomendado para pacientes frágeis)
002:20

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,39,1)
001:Clorambucil + Obinutuzumabe
002:15

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,51,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,52,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,53,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,2,56,1)
001:Clorambucil  (categoria 3)
002:3

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,1,1)
001:Acalabrutinibe
002:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,2,1)
001:Venetoclax
002:4

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,3,1)
001:FCR (Fludarabina + ciclofosfamida + Rituximab) (preferencialmente para pacientes com IGVH mutado)
002:16

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,7,1)
001:Ibrutinibe (categoria 1)
002:2

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,14,1)
001:Metilprednisolona em altas doses + Rituximabe (categoria 2B)
002:18

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,16,1)
001:Bendamustina + anticorpo monoclonal anti-CD20
002:14

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,18,1)
001:FR (Fludarabina + Rituximab) 
002:17

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,20,1)
001:PCR (Pentostatina + Ciclofosfamida + Rituximabe) (categoria 3)
002:19

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,3,50,1)
001:Ibrutinibe + Rituximabe (categoria 2B)
002:9

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,1,1)
001:Acalabrutinibe
002:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,7,1)
001:Ibrutinibe
002:2

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,13,1)
001:Alemtuzumabe + Rituximabe
002:11

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,14,1)
001:Metilprednisolona em altas doses + Rituximabe
002:12

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,4,15,1)
001:Obinutuzumabe
002:13

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,1,1)
001:Acalabrutinibe
002:1
003:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,2,1)
001:Venetoclax
002:4

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,11,1)
001:Clorambucil + Obinutuzumabe
002:15

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,14,1)
001:Metilprednisolona em altas doses + Rituximabe (categoria 2B)
002:18

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,15,1)
001:Obinutuzumabe (categoria 2B)
002:22

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,21,1)
001:Bendamustina (70mg/m2 no ciclo 1 com escalonamento para 90mg/m2 se bem tolerado) + anticorpo monoclonal anti-CD20 (não recomendado para pacientes frágeis)
002:20

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,39,1)
001:Clorambucil + Obinutuzumabe
002:15

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,51,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,52,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,53,1)
001:Rituximabe (categoria 3)
002:23

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,5,56,1)
001:Clorambucil  (categoria 3)
002:3

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,1,1)
001:Acalabrutinibe
002:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,2,1)
001:Venetoclax
002:4

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,3,1)
001:FCR (Fludarabina + ciclofosfamida + Rituximab) (preferencialmente para pacientes com IGVH mutado)
002:16

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,14,1)
001:Metilprednisolona em altas doses + Rituximabe (categoria 2B)
002:18

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,16,1)
001:Bendamustina + anticorpo monoclonal anti-CD20
002:14

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,18,1)
001:FR (Fludarabina + Rituximab) 
002:17

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,20,1)
001:PCR (Pentostatina + Ciclofosfamida + Rituximabe) (categoria 3)
002:19

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,6,50,1)
001:Ibrutinibe + Rituximabe (categoria 2B)
002:9

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,1,1)
001:Acalabrutinibe
002:1

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,6,1)
001:Acalabrutinibe + Obinutuzumabe
002:7

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,12,1)
001:Venetoclax + Obinutuzumabe
002:10

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,13,1)
001:Alemtuzumabe + Rituximabe
002:11

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,14,1)
001:Metilprednisolona em altas doses + Rituximabe
002:12

Location:^VARWorkFlowTerapiaMedicacao(0,"C91.1",1,7,15,1)
001:Obinutuzumabe
002:13

Node:^VARWorkFlowRegTera(0,"C91.1")
; Cadastro de Regismes Terapêuticos

Location:^VARWorkFlowRegTera(0,"C91.1",1,1)
001:Acalabrutinib
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",2,1)
001:Venetoclax Monoterapia
002:Precauções:<<<br>>>- Síndrome de lise tumoral ? Utilizar hipouricemiantes e hidratação adequada<<<br>>>- Neutropenia ? monitorar contagem de neutrófilos e utilizar fatores de crescimento se necessário.<<<br>>>- Infecções ? monitorar sinais e sintomas de infecção <<<br>>>- Vacinação ? Não administrar vacinas com vírus vivo atenuado antes, durante ou após tratamento com venetoclax, até normalização dos linfócitos B.<<<br>>>- Gestação ? este medicamento pode causar malformações congênitas.<<<br>>> Referências: <<<br>>>https://www.abbvie.com.br/content/dam/abbvie-dotcom/br/documents/VENCLEXTA-VP.pdf<<<br>>>Obs.: Este documento lista somente as precauções mais importantes relacionadas a este medicamento, e não deve, portanto, ser considerada uma relação completa. A bula do medicamento pode ser consultada para mais informações.<<<br>>><<<br>>>Terapia de Suporte: Venetoclax suporte<<<br>>>Se carga tumoral Baixa (linfocitose < 25.000/ul e ausência de linfonodos> 5cm):<<<br>>>- Preparação: 2 a 3 dias antes do início do tratamento	<<<br>>>     Agentes hipouricemiantes: Alopurinol<<<br>>>     Hidratação: 1,5 a 2 litros via oral<<<br>>>- Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico): Para doses iniciais de 20 e 50 mg: pré-dose, 6-8 horas e 24 horas. Para doses posteriores - pré-dose<<<br>>>Se carga tumoral Média  (linfocitose > 25.000/ul ou qualquer linfonodo entre 5 cm e 10 cm):<<<br>>> - Preparação: 2 a 3 dias antes do início do tratamento	<<<br>>>     Agentes hipouricemiantes: Alopurinol<<<br>>>     Hidratação: 1,5 a 2 litros via oral<<<br>>> - Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico): Para doses iniciais de 20 e 50 mg: pré-dose, 6-8 horas e 24 horas. Para doses posteriores - pré-dose. Considerar hospitalização para pacientes com clearence de creatinina < 80 ml/minuto<<<br>>>Se carga tumoral Alta (Qualquer linfonodo > 10 cm ou (linfocitose > 25.000/ul E qualquer linfonodo entre 5 cm e 10 cm):<<<br>>> - Preparação: 2 a 3 dias antes do início do tratamento	<<<br>>>     Agentes hipouricemiantes: Alopurinol ou Rasburicase (se ácido úrico elevado antes do tratamento)<<<br>>>     Hidratação: 1,5 a 2 litros via oral ou endovenoso (150 a 200 ml/hora se tolerado)<<<br>>> - Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico): Para doses iniciais de 20 e 50 mg: pré-dose, 4horas, 8 horas, 12 horas e 24 horas. Para doses posteriores - pré-dos, 6-8 horas e 24 horas
003:1
004:1
005:42

Location:^VARWorkFlowRegTera(0,"C91.1",3,1)
001:FCR (Fludarabina/Ciclofosfamida/Rituximab)
002:Preferencialmente para pacientes com IGVH mutado
003:1
004:2
005:43

Location:^VARWorkFlowRegTera(0,"C91.1",4,1)
001:BR (Bendamustina/Rituximab)
002:Terapia de Suporte: BR SUPORTE
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",5,1)
001:CC (Cladribina/Ciclofosfamida)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",6,1)
001:Acalabrutinib e Obinutuzumab
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",7,1)
001:Ibrutinib
002:Precauções:<<<br>>>- Diátese hemorrágica - Precaução em pacientes com diátese hemorrágica ou em tratamento com anticoagulantes ou duplo bloqueio de agregação plaquetária <<<br>>>- Cardiopatia ? Precaução em coronariopatia, insuficiência cardíaca congestiva, valvulopatias, arritmias e outras cardiopatias<<<br>>>- Infecções ? risco aumentado de infecções fúngicas invasivas, pneumonia, Varicela Zooster, pneumocystis jiroveci e reativação de hepatite B<<<br>>>- Interação medicamentosa - Evitar administração concomitante com agentes que interajam com CYP3A4, como cetoconazol, rifampicina, diltiazem, verapamil, amiodarona, fluconazol, voriconazol, etc. <<<br>>>Referências: PMID: 29255067, 31364186
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",8,1)
001:Ibrutinib e obinutuzumab
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",11,1)
001:Clorambucil e Obinutuzumab variante 1 (6 ciclos)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",12,1)
001:Venetoclax e Obinutuzumab
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",13,1)
001:Alemtuzumab e Rituximab
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",14,1)
001:HDMP-R (Metilprednisolona em altas doses e rituximab)
002:Terapia de suporte: Trimethoprim-Sulfamethoxazole (Bactrim DS) profilático até 2 meses após final do tratamento; Valacyclovir (Valtrex) profilático até 2 meses após o final do tratamento; Fluconazole (Diflucan) até 2 meses após o final do tratamento; Allopurinol (Zyloprim) 300 mg via oral, iniciar 3 dias antes do tratamento e manter durante o tratamento
003:1
004:2
005:46

Location:^VARWorkFlowRegTera(0,"C91.1",15,1)
001:Obinutuzumab
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",24,1)
001:Duvelisib
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",25,1)
001:Idelalisib e Rituximab
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",26,1)
001:Venetoclax e Rituximab
003:1
004:1

Location:^VARWorkFlowRegTera(0,"C91.1",27,1)
001:Idelalisib
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",28,1)
001:Lenalidomida e rituximab
002:Terapia de Suporte: Allopurinol (Zyloprim) 300 mg via oral, iniciar 3 dias antes do tratamento e manter durante o tratamento;Aspirin 81 mg via oral 1x ao dia enquanto usar lanalidomida;
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",36,1)
001:Bendamustina
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",37,1)
001:Clorambucil e rituximab (C_0,5mg/kg)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",38,1)
001:Clorambucil e rituximab variante 2 (C_8mg/m2)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",39,1)
001:Clorambucil e Obinutuzumab variante 2 (12 ciclos)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",40,1)
001:Ibrutinib e venetoclax
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",41,1)
001:Clorambucil e rituximab variante 3 (C_10mg/m2)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",42,1)
001:Venetoclax Suporte
002:Se carga tumoral Baixa (linfocitose < 25.000/ul e ausência de linfonodos> 5cm):<<<br>>>- Preparação: 2 a 3 dias antes do início do tratamento <<<br>>>     Agentes hipouricemiantes: Alopurinol<<<br>>>     Hidratação: 1,5 a 2 litros via oral<<<br>>>- Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico): Para doses iniciais de 20 e 50 mg: pré-dose, 6-8 horas e 24 horas. Para doses posteriores - pré-dose<<<br>>>Se carga tumoral Média  (linfocitose > 25.000/ul ou qualquer linfonodo entre 5 cm e 10 cm):<<<br>>> - Preparação: 2 a 3 dias antes do início do tratamento <<<br>>>     Agentes hipouricemiantes: <<<br>>>Alopurinol ? 300 mg via oral 1x ao dia por 7 dias<<<br>>>     Hidratação: 1,5 a 2 litros via oral<<<br>>> - Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico: Para doses iniciais de 20 e 50 mg: pré-dose, 6-8 horas e 24 horas. Para doses posteriores - pré-dose. Considerar hospitalização para pacientes com clearence de creatinina < 80 ml/minuto<<<br>>>Se carga tumoral Alta (Qualquer linfonodo > 10 cm ou (linfocitose > 25.000/ul E qualquer linfonodo entre 5 cm e 10 cm):<<<br>>> - Preparação: 2 a 3 dias antes do início do tratamento <<<br>>>     Agentes hipouricemiantes: <<<br>>>Alopurinol ? 300 mg via oral 1x ao dia por 7 dias<<<br>>>Ou, se ácido úrico elevado antes do tratamento<<<br>>>Rasburicase -  0.2 mg/kg endovenoso durante 30 minutos, 1x ao dia por até 5 dias<<<br>>>     Hidratação: 1,5 a 2 litros via oral ou endovenoso (150 a 200 ml/hora se tolerado)<<<br>>> - Início do Tratamento<<<br>>>     Monitoramento bioquímico potássio, cálcio, creatinina, fósforo e ácido úrico): Para doses iniciais de 20 e 50 mg: pré-dose, 4horas, 8 horas, 12 horas e 24 horas. Para doses posteriores - pré-dos, 6-8 horas e 24 horas
003:1
004:9
006:37

Location:^VARWorkFlowRegTera(0,"C91.1",43,1)
001:FCR suporte
003:1
004:9

Location:^VARWorkFlowRegTera(0,"C91.1",44,1)
001:Rituximab suporte
003:1
004:9
006:9913

Location:^VARWorkFlowRegTera(0,"C91.1",45,1)
001:Alemtuzumab Suporte
003:1
004:9
006:14767

Location:^VARWorkFlowRegTera(0,"C91.1",46,1)
001:HDMP-R (Metilprednisolona em altas doses e rituximab) Suporte
003:1
004:9

Location:^VARWorkFlowRegTera(0,"C91.1",47,1)
001:Obinutuzumab Suporte
003:1
004:9
006:14189

Location:^VARWorkFlowRegTera(0,"C91.1",48,1)
001:Lenalidomida Suporte
003:1
004:9
006:4125

Location:^VARWorkFlowRegTera(0,"C91.1",49,1)
001:Ofatumumabb Suporte
003:1
004:9
006:12843

Location:^VARWorkFlowRegTera(0,"C91.1",50,1)
001:Ibrutinib e Rituximab
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",51,1)
001:Rituximab monoterapia (R375 - 1 ciclo)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",52,1)
001:Rituximab monoterapia (R375/500 - 8 ciclos)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",53,1)
001:Rituximab monoterapia (R375/500 - 6 ciclos)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",54,1)
001:Lenalidomida (manutenção)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",55,1)
001:Ofatumumab (manutenção)
003:1
004:2

Location:^VARWorkFlowRegTera(0,"C91.1",56,1)
001:Clorambucil monoterapia
002:Precauções: mielosupressão<<<br>>>Exames de controle: hemograma
003:1
004:2

Node:^VARWorkFlowRegTeraCiclo(0,"C91.1")
; Ciclos do Regime Terapêutico

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",1,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",2,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",3,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",4,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",5,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",6,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",7,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",8,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",8,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",8,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",11,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,9,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,10,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,11,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",12,12,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",13,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",13,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",14,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",14,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",14,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,1,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,2,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,3,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,4,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,5,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,6,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,7,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",15,8,1)
001:21

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,9,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,10,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,11,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,12,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,13,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,14,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,15,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,16,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,17,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",24,18,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",25,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",25,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",25,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,9,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,10,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,11,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,12,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,13,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,14,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,15,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,16,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,17,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,18,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,19,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,20,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,21,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,22,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,23,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",26,24,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",27,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,1,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,2,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,3,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,4,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,5,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",28,6,1)
001:35

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",36,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",37,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",38,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,9,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,10,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,11,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",39,12,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,9,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,10,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,11,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,12,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,13,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,14,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,15,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,16,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,17,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,18,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,19,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,20,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,21,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,22,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,23,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",40,24,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",41,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",42,1,1)
001:7

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",42,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,1,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,2,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,3,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,4,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,5,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",43,6,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,1,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,2,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,3,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,4,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,5,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",44,6,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",45,1,1)
001:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",45,2,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",46,1,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",46,2,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",46,3,1)
001:30

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",47,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",48,1,1)

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",49,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,1,1)
002:1

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",50,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",51,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,7,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",52,8,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",53,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",54,7,1)

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",55,6,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,1,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,2,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,3,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,4,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,5,1)
001:28

Location:^VARWorkFlowRegTeraCiclo(0,"C91.1",56,6,1)
001:28

Node:^VARWorkFlowRegTeraCicloMed(0,"C91.1")
; Ciclos do Regime Terapêutico

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",1,1,1,1)
001:1810
002:100
003:1
004:1
005:4
010:ELEVATE TN
011:Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291
012:https://doi.org/10.1016/s0140-6736(20)30262-2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",2,1,1,1)
001:37
002:20
003:1
004:1
005:1
006:1
007:7
008:7
010:M12-175
011:M12-175: Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 Jan 28;374(4):311-22. Epub 2015 Dec 6.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1513257

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",2,1,2,1)
001:37
002:50
003:1
004:1
005:1
006:8
007:14
010:M13-982
011:M13-982: Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Heitner Enschede S, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 Jun;17(6):768-78. Epub 2016 May 10
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30019-5/fulltext

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",2,1,3,1)
001:37
002:100
003:1
004:1
005:1
006:15
007:21
010:M13-983
011:Update: Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. Epub 2018 May 1
012:https://pubmed.ncbi.nlm.nih.gov/29715056

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",2,1,4,1)
001:37
002:200
003:1
004:1
005:1
006:22
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",2,1,5,1)
001:37
002:400
003:1
004:1
005:1
006:29

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,1,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
011:Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4079-88. Epub 2005 Mar 14.
012:https://doi.org/10.1200/jco.2005.12.051

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,1,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL8
011:Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010 Oct 2;376(9747):1164-74
012:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961381-5/fulltext

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,1,3,1)
001:9913
002:375
003:3
004:2
005:1
006:0
007:0
008:28
010:GCLLSG CLL7
011:Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020 Feb 18. 
012:https://doi.org/10.1038/s41375-020-0747-7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,2,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
010:GOELAMS CLL2007FMP
011:Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14
012:http://www.bloodjournal.org/content/119/22/5104.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,2,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL10
011:Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. 
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,2,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
008:28
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,3,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
010:GOELAMS CLL2007FMP
011:Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14
012:http://www.bloodjournal.org/content/119/22/5104.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,3,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL10
011:Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. 
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,3,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
008:28
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,4,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
010:GOELAMS CLL2007FMP
011:Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14
012:http://www.bloodjournal.org/content/119/22/5104.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,4,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL10
011:Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. 
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,4,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
008:28
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,5,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
010:GOELAMS CLL2007FMP
011:Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14
012:http://www.bloodjournal.org/content/119/22/5104.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,5,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL10
011:Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. 
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,5,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
008:28
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,6,1,1)
001:7109
002:25
003:3
004:2
005:1
006:1
007:3
008:28
010:GOELAMS CLL2007FMP
011:Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, Béné MC, Letestu R, Cymbalista F, Feugier P. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012 May 31;119(22):5104-10. Epub 2012 Feb 14
012:http://www.bloodjournal.org/content/119/22/5104.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,6,2,1)
001:2240
002:250
003:3
004:2
005:1
006:1
007:3
008:28
010:GCLLSG CLL10
011:Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; International Group of Investigators; German CLL Study Group. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. 
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30051-1/abstract

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",3,6,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
008:28
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443.
012:https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,1,1,1)
001:9294
002:70
003:3
004:2
005:1
006:1
007:2
011:Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM; GCLLSG. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 Sep 10;29(26):3559-66. Epub 2011 Aug 15
012:http://jco.ascopubs.org/content/29/26/3559.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,1,2,1)
001:9913
002:375
003:3
004:2
005:1
006:0
007:0
010:HELIOS
011:Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. Epub 2015 Dec 5
012:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00465-9/fulltext

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,2,1,1)
001:9294
002:90
003:3
004:2
005:1
006:1
007:2
010:TUGELA
011:Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28.
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,2,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
010:MABLE
011:Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,3,1,1)
001:9294
002:90
003:3
004:2
005:1
006:1
007:2
010:TUGELA
011:Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28.
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
010:MABLE
011:Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,4,1,1)
001:9294
002:90
003:3
004:2
005:1
006:1
007:2
010:TUGELA
011:Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28.
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,4,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
010:MABLE
011:Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,5,1,1)
001:9294
002:90
003:3
004:2
005:1
006:1
007:2
010:TUGELA
011:Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28.
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,5,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
010:MABLE
011:Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,6,1,1)
001:9294
002:90
003:3
004:2
005:1
006:1
007:2
010:TUGELA
011:Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017 Mar;18(3):297-311. Epub 2017 Jan 28.
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589180/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",4,6,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1
010:MABLE
011:Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706. Epub 2018 Feb 1
012:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865431/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,1,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,1,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,2,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,2,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,3,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,3,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,4,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,4,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,5,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,5,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,6,1,1)
001:9258
002:.12
003:4
004:2
005:1
006:1
007:3
010:PALG CLL2
011: Robak T, Blonski JZ, Gora-Tybor J, Jamroziak K, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszynska A, Kowal M, Kloczko J, Stella-Holowiecka B, Sulek K, Calbecka M, Zawilska K, Kuliczkowski K, Skotnicki AB, Warzocha K, Kasznicki M; PALG. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood. 2006 Jul 15;108(2):473-9. Epub 2006 Mar 21.
012:http://www.bloodjournal.org/content/108/2/473.long

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",5,6,2,1)
001:2240
002:650
003:3
004:2
005:1
006:1
007:1
011:Robak T, Blonski JZ, Gora-Tybor J, Calbecka M, Dwilewicz-Trojaczek J, Boguradzki P, Dmoszynska A, Kowal M, Kloczko J, Piszcz J, Stella-Holowiecka B, Sulek K, Kuliczkowski K, Potoczek S, Warzocha K, Lech-Maranda E, Skotnicki AB, Piotrowska M, Moskwa A, Zawilska K, Jamroziak K. Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Mar;55(3):606-10. Epub 2013 Nov 14
012:https://pubmed.ncbi.nlm.nih.gov/23721512

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,1,1,1)
001:1810
002:100
003:1
004:1
005:4
010:ELEVATE TN
011:Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291
012:https://pubmed.ncbi.nlm.nih.gov/32305093

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,2,2,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,2,3,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,2,4,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,2,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,3,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,4,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,5,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,6,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",6,7,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",7,1,1,1)
001:9229
002:420
003:1
004:1
005:1
010:PCYC-1102
011:O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58. Epub 2013 Dec 10
012:https://pubmed.ncbi.nlm.nih.gov/25700432/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,1,1,1)
001:9229
002:420
003:1
004:1
005:1
010:iLLUMINATE
011:Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):43-56. <<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/30522969/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,2,2,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,2,3,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,2,4,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,2,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",8,3,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1
010:GCLLSG CLL11
011:Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. Epub 2014 Jan 8
012:https://pubmed.ncbi.nlm.nih.gov/24401022/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,3,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1
011:Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/25634683/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,4,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,1,6,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,2,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,2,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,2,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,3,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,3,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,3,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,4,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,4,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,4,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,5,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,5,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,5,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,6,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,6,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",11,6,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,1,1,1)
001:37
002:20
003:1
004:1
005:1
006:22
007:28
010:GCLLSG CLL14
011:Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. Epub 2019 Jun 4
012:https://pubmed.ncbi.nlm.nih.gov/31166681

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,1,2,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,1,3,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,1,4,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,1,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,2,1,1)
001:37
002:50
003:1
004:1
005:1
006:1
007:7
011:Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1188-1200
012:https://pubmed.ncbi.nlm.nih.gov/32888452/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,2,2,1)
001:37
002:100
003:1
004:1
005:1
006:8
007:14

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,2,3,1)
001:37
002:200
003:1
004:1
005:1
006:15
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,2,4,1)
001:37
002:400
003:1
004:1
005:1
006:22
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,2,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,3,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,3,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,4,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,4,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,5,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,5,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,6,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,6,2,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,7,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,8,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,9,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,10,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,11,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",12,12,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,1,1)
001:14767
002:3
003:1
004:2
005:1
006:1
007:1
010:Faderl et al. 2003
011:Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-5. 
012:https://pubmed.ncbi.nlm.nih.gov/12522009

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,2,1)
001:14767
002:10
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,3,1)
001:14767
002:30
003:1
004:2
005:1
006:3
007:3

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,4,1)
001:14767
002:30
003:1
004:2
005:1
006:10
007:10

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,5,1)
001:14767
002:30
003:1
004:2
005:1
006:12
007:12

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,6,1)
001:14767
002:30
003:1
004:2
005:1
006:17
007:17

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,7,1)
001:14767
002:30
003:1
004:2
005:1
006:19
007:19

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,8,1)
001:14767
002:30
003:1
004:2
005:1
006:24
007:24

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,9,1)
001:14767
002:30
003:1
004:2
005:1
006:26
007:26

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,10,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,11,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,12,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,1,13,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,1,1)
001:14767
002:3
003:1
004:2
005:1
006:1
007:1
010:Faderl et al. 2003
011:Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-5. 
012:https://pubmed.ncbi.nlm.nih.gov/12522009

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,2,1)
001:14767
002:10
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,3,1)
001:14767
002:30
003:1
004:2
005:1
006:3
007:3

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,4,1)
001:14767
002:30
003:1
004:2
005:1
006:10
007:10

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,5,1)
001:14767
002:30
003:1
004:2
005:1
006:12
007:12

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,6,1)
001:14767
002:30
003:1
004:2
005:1
006:17
007:17

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,7,1)
001:14767
002:30
003:1
004:2
005:1
006:19
007:19

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,8,1)
001:14767
002:30
003:1
004:2
005:1
006:24
007:24

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,9,1)
001:14767
002:30
003:1
004:2
005:1
006:26
007:26

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,10,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,11,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,12,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",13,2,13,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,1,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
011:Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20.
012:https://pubmed.ncbi.nlm.nih.gov/19693094

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,1,2,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,1,3,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,1,4,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,1,5,1)
001:2529
002:1000
003:3
004:2
005:1
006:1
007:3

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,2,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
011:Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20.
012:https://pubmed.ncbi.nlm.nih.gov/19693094

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,2,2,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,2,3,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,2,4,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,2,5,1)
001:2529
002:1000
003:3
004:2
005:1
006:1
007:3

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,3,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
011:Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009 Oct;23(10):1779-89. Epub 2009 Aug 20.
012:https://pubmed.ncbi.nlm.nih.gov/19693094

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,3,2,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,3,3,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,3,4,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",14,3,5,1)
001:2529
002:1000
003:3
004:2
005:1
006:1
007:3

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,1,1,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1
010:Salles et al. 2012 (GAUGUIN)
011:Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012 May 31;119(22):5126-32. Epub 2012 Mar 19.
012:https://pubmed.ncbi.nlm.nih.gov/22431570

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,1,2,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,1,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,1,4,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,2,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,3,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,4,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,5,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,6,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,7,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",15,8,1,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,1,1,1)
001:17906
002:25
003:1
004:1
005:4
010:DUO
011:Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 Dec 6;132(23):2446-2455

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,2,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,3,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,4,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,5,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,6,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,7,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,8,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,9,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,10,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,11,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,12,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,13,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,14,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,15,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,16,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,17,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",24,18,1,1)
001:17906
002:25
003:1
004:1
005:4

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,1,1,1)
001:17905
002:150
003:1
004:1
005:10
006:1
007:336
010:Study 101-08
011:O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. Epub 2015 Oct 15.
012:https://pubmed.ncbi.nlm.nih.gov/26472751/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,2,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,2,3,1)
001:9913
002:500
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,2,4,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,2,5,1)
001:9913
002:500
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,3,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,3,3,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",25,3,4,1)
001:9913
002:500
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,1,1,1)
001:37
002:20
003:1
004:1
005:1
006:1
007:7
010:MURANO
011:Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019 Feb 1;37(4):269-277.
012:https://pubmed.ncbi.nlm.nih.gov/30523712/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,1,2,1)
001:37
002:50
003:1
004:1
005:1
006:8
007:14

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,1,3,1)
001:37
002:100
003:1
004:1
005:1
006:15
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,1,4,1)
001:37
002:200
003:1
004:1
005:1
006:22
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,2,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,2,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,3,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,4,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,4,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,5,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,5,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,6,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,6,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,7,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,7,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,8,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,9,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,10,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,11,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,12,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,13,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,14,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,15,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,16,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,17,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,18,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,19,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,20,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,21,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,22,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,23,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",26,24,1,1)
001:37
002:400
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",27,1,1,1)
001:17905
002:150
003:1
004:1
005:4
010:DELTA
011:Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008-18. Epub 2014 Jan 22.
012:https://pubmed.ncbi.nlm.nih.gov/24450858/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,1,1,1)
001:4125
002:2.5
003:1
004:1
005:1
006:1
007:7
010:James et al. 2014 (CRC014)
011:CRC014: James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol. 2014 Jul 1;32(19):2067-73. Epub 2014 May 27.<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/24868031

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,1,2,1)
001:4125
002:5
003:1
004:1
005:1
006:8
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,1,3,1)
001:9913
002:375
003:3
004:2
005:1
006:31
007:31

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,1,4,1)
001:9913
002:375
003:3
004:2
005:1
006:33
007:33

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,2,1,1)
001:4125
002:5
003:1
004:1
005:1
006:1
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,2,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,2,3,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,2,4,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,2,5,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,3,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,3,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,4,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,4,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,5,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,5,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,6,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",28,6,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,1,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,2,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,3,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,4,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,5,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",36,6,1,1)
001:9294
002:100
003:3
004:2
005:1
006:1
007:2
010:Knauf et al. 2009
011:Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009 Sep 10;27(26):4378-84<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/19652068

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,1,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1
010:Goede et al. 2014 (GCLLSG CLL11)
011:Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. 
012:https://pubmed.ncbi.nlm.nih.gov/25634683/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,1,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15
010:Goede et al. 2014 (GCLLSG CLL11)
011:Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. <<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/25634683/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,1,3,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,2,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,2,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,2,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,3,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,3,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,3,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,4,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,4,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,4,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,5,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,5,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,5,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,6,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,6,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",37,6,3,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,1,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7
010:Foà et al. 2014 (ML21445)
011:ML21445: Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014 May;89(5):480-6.
012:https://pubmed.ncbi.nlm.nih.gov/24415640

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,1,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,2,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,2,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,3,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,4,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,4,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,5,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,5,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,6,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,6,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,7,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,7,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,8,1,1)
001:1749
002:8
003:4
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",38,8,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1
010:GCLLSG CLL14
011:Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 Jun 6;380(23):2225-2236. 
012:https://pubmed.ncbi.nlm.nih.gov/31166681/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,3,1)
001:14189
002:100
003:1
004:2
005:1
006:1
007:1
011:Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, Montillo M, Fegan C, Asikanius E, Humphrey K, Fingerle-Rowson G, Hallek M. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015 Jul;29(7):1602-4. Epub 2015 Jan 30<<<br>>>
012:https://pubmed.ncbi.nlm.nih.gov/25634683/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,4,1)
001:14189
002:900
003:1
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,5,1)
001:14189
002:1000
003:1
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,1,6,1)
001:14189
002:1000
003:1
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,2,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,2,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,2,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,3,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,3,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,3,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,4,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,4,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,4,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,5,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,5,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,5,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,6,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,6,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,6,3,1)
001:14189
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,7,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,7,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,8,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,8,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,9,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,9,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,10,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,10,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,11,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,11,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,12,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",39,12,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,1,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,2,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,3,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,4,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,4,2,1)
001:37
002:20
003:1
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,4,3,1)
001:37
002:50
003:1
004:1
005:1
006:8
007:14

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,4,4,1)
001:37
002:100
003:1
004:1
005:1
006:15
007:21

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,4,5,1)
001:37
002:200
003:1
004:1
005:1
006:22
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,5,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,5,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,6,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,6,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,7,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,7,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,8,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,8,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,9,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,9,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,10,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,10,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,11,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,11,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,12,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,12,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,13,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,13,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,14,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,14,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,15,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,15,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,16,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,16,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,17,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,17,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,18,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,18,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,19,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,19,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,20,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,20,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,21,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,21,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,22,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,22,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,23,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,23,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,24,1,1)
001:9229
002:420
003:1
004:1
005:1
010:MDACC 2015-0860
011:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019 May 30;380(22):2095-2103.
012:https://pubmed.ncbi.nlm.nih.gov/31141631/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",40,24,2,1)
001:37
002:400
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,1,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7
010:Hillmen et al. 2014 (NCRI CLL208)
011:NCRI CLL08: Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014 Apr 20;32(12):1236-41. 
012:https://pubmed.ncbi.nlm.nih.gov/24638012/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,1,2,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
010:Michallet et al. 2018 (MABLE)
011:MABLE: Michallet AS, Aktan M, Hiddemann W, Ilhan O, Johansson P, Laribi K, Meddeb B, Moreno C, Raposo J, Schuh A, Ünal A, Widenius T, Bernhardt A, Kellershohn K, Messeri D, Osborne S, Leblond V. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica. 2018 Apr;103(4):698-706.

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,2,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,2,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,3,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,4,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,4,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,5,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,5,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,6,1,1)
001:1749
002:10
003:3
004:1
005:1
006:1
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",41,6,2,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",42,1,1,1)
001:1772
002:300
003:1
004:1
005:1x ao dia
006:por 7 dias
007:7

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",42,1,2,1)
001:14726
002:.2
003:4
004:2
005:1x ao dia
006:Por até 5 dias
007:5
011:Via de Administração: endovenoso (em 30 minutos)<<<br>>>Dias de tratamento: Por até 5 dias

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,1,3,1)
001:1772
002:300
003:1
004:1
005:1x ao dia
006:Por 7 dias

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,1,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,1,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,2,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,2,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,3,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,3,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,3,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,3,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,4,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,4,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,4,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,4,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,5,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,5,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,5,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,5,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,6,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab
007:0

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,6,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,6,4,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",43,6,6,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até o término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,3,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,3,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,4,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,4,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,5,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,5,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,6,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",44,6,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,1,3,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,1,5,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,2,3,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",45,2,5,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,3,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,5,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,6,1)
001:1706
002:100
003:1
004:1
005:1x por dia
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,1,7,1)
001:1772
002:300
003:1
004:1
005:1x ao dia
006:Por 7 dias

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,2,3,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,2,5,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,2,6,1)
001:1706
002:100
003:1
004:1
005:1x por dia
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,3,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,3,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,3,3,1)
001:6259
002:800/160
003:1
004:1
005:2x por semana
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,3,5,1)
001:257
002:400
003:1
004:1
005:12/12h
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",46,3,6,1)
001:1706
002:100
003:1
004:1
005:1x por dia
006:contínuo, até 2 meses após término do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,1,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,2,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,3,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,3,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,3,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,4,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,4,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,4,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,5,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,5,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,5,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,6,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,6,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",47,6,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",48,1,1,1)
001:1772
002:300
003:1
004:1
005:1x ao dia
006:por 14 dias

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",48,1,2,1)
001:2106
002:81
003:1
004:1
005:1x ao dia
006:até o fim do tratamento

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,1,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,1,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,1,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,2,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,2,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,2,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,3,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,3,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,3,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,4,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,4,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,4,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,5,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,5,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,5,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,6,1,1)
001:4347
002:25
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,6,2,1)
001:494
002:650
003:1
004:1
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",49,6,3,1)
001:850
002:100
003:1
004:2
005: 
006:30 minutos antes da infusão de rituximab

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,1,1,1)
001:9229
002:420
003:1
004:1
005:1
010:ECOG E1912
011:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 Aug 1;381(5):432-443
012:https://pubmed.ncbi.nlm.nih.gov/31365801

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,2,2,1)
001:9913
002:50
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,2,3,1)
001:9913
002:325
003:3
004:2
005:1
006:2
007:2

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,3,2,1)
001:9913
002:325
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,4,2,1)
001:9913
002:325
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,5,2,1)
001:9913
002:325
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,6,2,1)
001:9913
002:325
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",50,7,1,1)
001:9913
002:325
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",51,1,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
010:RESORT substudy
011:Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS; Eastern Cooperative Oncology Group. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun;173(6):867-75.
012:https://pubmed.ncbi.nlm.nih.gov/26970533

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",51,1,2,1)
001:9913
002:375
003:3
004:2
005:1
006:8
007:8

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",51,1,3,1)
001:9913
002:375
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",51,1,4,1)
001:9913
002:375
003:3
004:2
005:1
006:22
007:22

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,1,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
010:GS-US-312-0116
011:Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007.
012:https://pubmed.ncbi.nlm.nih.gov/24450857

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,2,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,3,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,4,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,5,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,6,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,7,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",52,8,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,1,1,1)
001:9913
002:375
003:3
004:2
005:1
006:1
007:1
010:CR102604
011:Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, Hu J, Hu Y, Ke X, Li J, Liang Y, Liu T, Lv Y, Ren H, Sun A, Wang J, Zhao C, Salman M, Sun S, Howes A, Wang J, Wu P, Li J. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med. 2018 Apr;7(4):1043-1055.
012:https://pubmed.ncbi.nlm.nih.gov/29533000

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,1,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,2,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,2,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,3)
001:14496
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,3,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,3,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,4)
001:14496
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,4,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,4,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,5)
001:14496
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,5,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,5,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,6)
001:14496
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,6,1,1)
001:9913
002:500
003:3
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",53,6,2,1)
001:9913
002:500
003:3
004:2
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,1,1,1)
001:4125
002:5
003:1
004:1
005:1
006:1
007:28
010:GCLLSG CLLM1
011:Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct;4(10):e475-e486. 
012:https://pubmed.ncbi.nlm.nih.gov/28916311/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,2,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,3,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,4,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,5,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,6,1,1)
001:4125
002:10
003:1
004:1
005:1
006:1
007:28

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",54,7,1,1)
001:4125
002:15
003:1
004:1
005:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,1,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1
010:Strati et al. 2016
011:Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep;3(9):e407-14.
012:https://pubmed.ncbi.nlm.nih.gov/27570087/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,2,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,3,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,4,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,5,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",55,6,1,1)
001:12843
002:1000
003:1
004:2
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,1,1,1)
001:1749
002:0.5
003:4
004:1
005:1
006:1
007:1
010:RESONATE-2
011:Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015 Dec 17;373(25):2425-37. 
012:https://pubmed.ncbi.nlm.nih.gov/26639149/

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,1,2,1)
001:1749
002:0.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,2,1,1)
001:1749
002:0.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,2,2,1)
001:1749
002:0.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,3,1,1)
001:1749
002:0.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,3,2,1)
001:1749
002:0.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,4,1,1)
001:1749
002:0.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,4,2,1)
001:1749
002:0.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,5,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,5,2,1)
001:1749
002:.5
003:4
004:1
005:1
006:15
007:15

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,6,1,1)
001:1749
002:.5
003:4
004:1
005:1
006:1
007:1

Location:^VARWorkFlowRegTeraCicloMed(0,"C91.1",56,6,2,1)
001:1749
002:0.5
003:4
004:1
005:1
006:15
007:15
